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Occurrence and seasonal variability of selected pharmaceuticals in Southern Ontario 
drinking water supplies 
 The presence and seasonal variability of human and veterinary pharmaceuticals in 
surface water (raw water) and treated water samples from two drinking water facilities in 
Southern Ontario was investigated.  Water samples were collected at monthly intervals for 
one year to characterize the seasonal variability of these contaminants.  The presence of these 
compounds in raw water samples collected from groundwater wells, which were potentially 
under the influence of surface water, was also examined. All samples were extracted by solid 
phase extraction (SPE) techniques and analyzed by liquid chromatography coupled with 
tandem mass spectrometry (LC-ESI-MS/MS). The compounds detected represented different 
therapeutic classes, including antibiotics, lipid regulating agents and anti-inflammatory drugs. 
The concentrations detected for most compounds were in the low ng/L range, with one 
compound being detected close to 1 µg/L.  In general, human pharmaceuticals (i.e. 
gemfibrozil, ibuprofen and carbamazepine) were detected in raw and treated water samples, 
while the antibiotics were not detected after treatment.  Seasonal variability was observed in 
the concentrations and compounds detected, which could be partially explained by changes in 
surface water hydrology and sources of contamination.  The results demonstrate that the 
application of conventional treatment technologies were not very effective in reducing some 
of these compounds from a drinking water facility.  In contrast, a second drinking water 
facility using additional treatment technologies, including ozonation and granular activated 
carbon (GAC) filters, could reduce the concentrations of these contaminants.  Although, the 
presence of these contaminants in surface water represents a potential risk, the results suggest 
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In the last 15 years, research investigating environmental impacts of contaminants has 
begun to focus on a number of “emerging” contaminants. One group of “emerging” 
contaminants is a widely diverse group of biologically active compounds, which are 
commonly referred to as pharmaceuticals and active agents in personal care products (PPCPs) 
(Daughton and Ternes, 1999).  This large group consists of non-prescription drugs, 
prescription drugs, veterinary medicines, growth promoters, diagnostic agents, cosmetics, 
fragrances, sun screen agents, musks and disinfectants used in industry, households and 
agricultural practices (Halling-Sørensen et al., 1998; Barceló and Petrović, 2007).   
Although, these compounds have only recently been recognized as environmental 
contaminants, they have gained the attention of the general public and the scientific 
community.  Concern has been raised based on their continuous release into the environment 
at low concentrations and the possible subtle effects of these compounds on non-target 
organisms over an extended period of time (Jones et al., 2005; Barceló and Petrović, 2007). 
In contrast to other environmental contaminants, pharmaceuticals are designed to be 
biologically active and have specific modes of action to help prevent, treat or cure health 
conditions in humans as well as animals (i.e. fish, cattle, swine and poultry) (Derksen et al., 
2004; Bendz et al., 2005). The application of these compounds in healthcare is considered to 
be one of the greatest benefits in modern society, and has improved the health and lifestyle of 
individuals dealing with a diversity of specific health problems (Roberts and Bersuder, 2006). 
However, limited attention has been given to the possible impacts these compounds may have 
on ecosystem health (O’Brien and Dietrich, 2004).  Regulations and guidelines for these 
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compounds are now being explored to control their release and potential impacts in the 
environment (EMEA, 2006a; EMEA 2006b). 
Some of the first reports of pharmaceuticals detected in the environment were in the 
1970’s when clofibric acid was detected in wastewater samples collected in the United States 
(Garrison et al., 1976; Jones et al., 2001).  However, limited attention was given to the 
presence of these contaminants in the environment until the early 1990’s when clofibric acid 
was detected in groundwater and tap water samples collected in Germany (Stan and Heberer, 
1997; Heberer et al., 1998; Heberer et al, 2002; Jones et al., 2005). Clofibric acid was the first 
pharmaceutical to be reported in tap water samples with concentrations up to 270 ng/L 
(Heberer, 2002b; Jones et al., 2005).  In recent years, advancements in analytical methods 
have contributed to the detection of over 100 active agents in pharmaceutical products in 
different environmental matrices (Richardson and Ternes, 2005; Zwiener, 2007).  It is 
anticipated that this number will continue to grow as more pharmaceutical products are 
approved for use and advancements in analytical methods continue.   
1.1 Development of Analytical Methods 
Advancements made in environmental and analytical chemistry with the combination 
of liquid chromatography and mass spectrometry (LC-MS or LC-MS/MS) has allowed 
researchers to confidently detect these compounds in complex matrices at low concentrations 
(Niessen, 1998; Zwiener and Frimmel, 2004).  LC-MS with electrospray ionization (ESI) has 
commonly been applied as a selective and sensitive tool for the detection of PPCPs in 
biological and environmental matrices because of the polar, thermoliable and non-volatile 
nature of these contaminants (Hernando et al., 2004; Zwiener and Frimmel, 2004). Niessen 
(1998) reported that approximately 95% of LC-MS work uses ESI or atmospheric pressure 
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chemical ionization (APCI) as the ionization source, however ESI is most commonly used in 
the detection of PPCPs in environmental matrices.  The major disadvantage of using LC-MS 
with ESI is the potential of matrix effects occurring during the ionization of the analytes in the 
source interface (Petrović et al., 2005).  Matrix effects are defined as a change in analyte 
signal caused by something in the sample other than the analyte (Harris, 1999).  During 
method development, the identification and correction for possible matrix effects must be 
accomplished to achieve accurate measurements.  If matrix effects are not addressed an 
overestimation or underestimation of the actual environmental concentration can occur, and 
the accuracy of the method is impacted (Van De Steene et al., 2006).  
Matrix effects are observed when the signal intensity of an analyte detected in a field 
sample is different from the signal intensity detected in a solvent solution (Miao and Metcalfe, 
2003; Hernando et al., 2004).  Studies have shown that an increase in the amount of matrix 
present (i.e. organic material) results in signal suppression or enhancement, with higher ion 
suppression occurring in wastewater influent and effluent samples (Hirsh et al., 1998; Miao 
and Metcalfe, 2003; Vanderford et al., 2003; Hernando et al., 2004; Vieno et al., 2006).  
However, the impact that the matrix has on a compound is dependent on the analyte as well as 
the composition of the matrix.   
The best approach to compensate for matrix effects is the use of internal standards 
(isotopically labeled standards), which elute from the separation column at a similar retention 
time and undergo the same conditions in the ionization source.  Recent studies investigating 
the presence of pharmaceuticals in complex matrices have incorporated the use of internal 
standards into their methods to correct for matrix effects.  The disadvantage of using these 
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labeled standards is the cost of purchasing them and the availability of them for use in 
research. 
Matrix effects can also be addressed by using a standard addition approach, improving 
clean-up and extraction procedures to reduce the amount of matrix entering the instrument, 
reducing the flow rate of the sample matrix into the ionization source, and decreasing the 
injection volume (Hernando et al., 2004; Gómez et al., 2006; Kloepfer et al., 2005; Van De 
Steene et al., 2006).  The application of all these approaches have been useful in reducing 
matrix effects, but all exhibit some limitations, including decreases in sensitivity, and 
increases in time and labour costs.  
Advancements made in this area of environmental chemistry have allowed researchers 
to determine the occurrence of pharmaceuticals in the environment and apply this information 
to help assess the impacts of these compounds on environmental and human health. 
1.2 Entry into the Environment 
Pharmaceuticals are ubiquitous environmental contaminants, and have been detected 
in raw and treated wastewater, soil, biosolids, sediment, groundwater, surface water and 
drinking water supplies in North America and Europe (Ternes et al., 2001; Sacher et al., 2001; 
Heberer et al., 2002; Löffler and Ternes, 2003, Metcalfe et al., 2003a; Ashton et al., 2004; 
Miao et al., 2005; Vanderford and Snyder, 2006; Gómez et al., 2007).  The concentrations 
detected have been relatively low, with concentrations in the µg/L range for wastewater 
samples, and in the low ng/L range for drinking water. 
Reviews by Halling-Sørensen et al. (1998), Ternes (1998), Heberer (2002b) and 
Derksen et al. (2004) have illustrated possible exposure routes for the entry of human and 
veterinary pharmaceuticals into the environment.   Human pharmaceuticals enter the 
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environment mainly through their therapeutic use.  The drug is excreted via urine or feces as 
various combinations of metabolites, the parent compound or conjugated compounds 
(Halling-Sørensen et al., 1998).  In the body, most drugs are metabolized to some extent by 
phase I and/or phase II reactions before leaving the body and entering the environment.  Phase 
I reactions include oxidation, reduction and hydroxylation reactions, and produce reactive 
water-soluble compounds which can either add or expose functional groups needed for further 
reactions (Halling-Sørensen et al., 1998; Josephy and Mannervik, 2006).  Phase II reactions, 
also called conjugation reactions, involve the binding of functional groups to the compound, 
which increases its water solubility for elimination from the body.  Phase II reactions include 
sulfation, methylation, acetylation, glutathione conjugation and glucuronide conjugation 
(Josephy and Mannervik, 2006).   
The release of human pharmaceuticals and/or its metabolites into the aquatic 
environment can occur through a number of different exposure pathways, including surface 
runoff after the application of biosolids, disposal of pharmaceutical production wastes and 
discharging of hospital wastewater effluents (Halling-Sørensen et al., 1998; Daughton and 
Ternes, 1999; Gómez et al., 2006).  However, the major route by which human 
pharmaceuticals and their metabolites enter the aquatic environment is through the 
discharging of these compounds into surface waters from domestic waste after incomplete 
removal during wastewater treatment (Ternes, 1998; Heberer et al., 2002; Metcalfe et al., 
2003b; Bendz et al., 2005; Lishman et al., 2006).  This route also provides a significant 
pathway for how these compounds can contaminate source waters for drinking water 
production.   
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The release of veterinary pharmaceuticals into the environment can take place directly 
when the livestock animals are on pasture or indirectly by run-off or leaching through the soil 
(Derksen et al., 2004).  Veterinary pharmaceuticals can also be released into the environment 
after the stored manure is applied onto agricultural land during the spring and fall months as a 
soil amendment.  Surface runoff and leaching after the application of manure depends on a 
number of parameters, including climatological conditions as well as the physical and 
chemical properties of the compound (Derksen et al., 2004).   
In either case, for human and veterinary pharmaceuticals, these compounds will 
eventually enter surface waters or infiltrate into groundwater aquifers, which can be used for 
potable water use (Jones et al., 2001).  The concern of drinking water supplies contaminated 
with PPCPs will continue to grow as urbanization and intensification of animal production 
increases.   
1.3 Presence of Pharmaceuticals in the Canadian Environment 
 In Canada, research has focused on determining the presence of selected 
pharmaceuticals in wastewater treatment facilities and surface waters (Metcalfe et al., 2003a; 
Metcalfe et al., 2003b; Brun et al., 2006; Lishman et al., 2006), as well as surface waters 
exposed to agricultural inputs (Hao et al., 2006; Lissemore et al., 2006).  Hao et al. (2006) and 
Lissemore et al. (2006) investigated the presence of pharmaceuticals (antibiotics, acidic and 
neutral pharmaceuticals) in surface waters receiving agricultural inputs as well as one 
sampling location near an urbanized area in a Southern Ontario watershed.  The authors 
reported the presence of selected pharmaceuticals, with lincomycin HCl, trimethoprim, 
sulfamethazine, carbamazepine and monensin being the most frequently detected. 
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Brun et al. (2006) investigated the presence of neutral and acidic drugs in wastewater 
treatment facilities and surface waters in Atlantic Canada.  High concentrations of bezafibrate, 
gemfibrozil, ibuprofen, naproxen and carbamazepine were detected in wastewater effluent 
samples.  The highest median concentrations was for ibuprofen and naproxen with median 
concentrations over 1000 ng/L during the spring and summer months.  Carbamazepine was 
detected at lower concentrations compared to the acidic drugs, but the concentrations were 
more consistent over the sampling period.  The presence of bezafibrate, gemfibrozil and 
carbamazepine were sparse, with median concentrations below 20 ng/L.  The concentrations 
of the selected pharmaceuticals decreased when samples were collected further downstream 
from wastewater effluent discharge location or the receiving environment merged with other 
water bodies to dilute the percentage of the wastewater effluents in the surface waters (Brun et 
al., 2006).   
A recent study by Verenitch et al. (2006) detected similar results as Brun et al. (2006) 
in which human pharmaceuticals were detected in wastewater effluents collected on the West 
Coast of Canada.  The concentrations were above 1µg/L in the effluent samples and 
significantly lower concentrations in the samples collected in the receiving waters.  
Lishman et al. (2006) investigated the presence and possible reductions of acidic drugs 
in the Thames River watershed in Southwestern Ontario.  Ibuprofen, gemfibrozil and 
naproxen were some of the compounds detected in final wastewater effluent samples, with 
median percent reductions of greater than 90% for ibuprofen and naproxen and 66% for 
gemfibrozil.  The median concentrations detected in the final wastewater effluent samples 
were 500 ng/L or lower for the acidic pharmaceuticals. 
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 Metcalfe et al. (2003a) detected the presence of acidic and neutral drugs in influent 
and effluent samples collected from a number of Canadian wastewater treatment facilities.  
The most frequently detected compounds included salicylic acid, naproxen, ibuprofen, 
gemfibrozil and carbamazepine.  Metcalfe et al. (2003b) investigated the presence of acidic 
and neutral pharmaceuticals in four wastewater treatment facilities and surface waters located 
near wastewater treatment facilities in selected regions of Ontario.  The compounds detected 
during the sampling period included carbamazepine, ibuprofen, gemfibrozil, bezafibrate, 
naproxen and trimethoprim along with other anti-inflammatory agents and clofibric acid.   
Hua et al. (2006b) investigated the same compounds as Metcalfe et al. (2003a and 
2003b) but concentrated on the presence of these compounds in one wastewater treatment 
facility in Windsor, Ontario and along the shoreline of two rivers.  Ibuprofen, naproxen, 
bezafibrate, gemfibrozil, carbamazepine and trimethoprim were found at high concentrations.  
The concentrations of bezafibrate and carbamazepine were relatively consistent over the three 
sampling months.  Higher concentrations of gemfibrozil and trimethoprim were detected in 
samples collected during March and June compared to September.  The concentrations of 
ibuprofen over the three sampling months were quite random with higher concentrations 
detected in September and March.  Naproxen was detected at relatively high concentrations 
over each sampling month, with lower concentrations detected in March.  The concentrations 
of these compounds dramatically decreased downstream of wastewater effluent discharge site 
due to the effluent being diluted by large water bodies, with most concentrations below 100 
ng/L where the two rivers joined. 
 The presence of acidic pharmaceuticals, carbamazepine and its metabolites, and anti-
microbials have been detected in a number of wastewater treatment facilities in Canada, with 
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concentrations in the low µg/L range (Miao et al., 2002; Miao et al., 2004; Miao et al., 2005). 
Selected statin drugs have also been detected in wastewater influent and effluent samples as 
well as surface water samples in Ontario, but were found at lower concentrations compared to 
other pharmaceuticals (Miao and Metcalfe, 2003). 
 The results from the studies conducted in Canada illustrate that pharmaceuticals are 
widespread contaminants in Canadian wastewater treatment facilities and surface waters. 
Research has shown the presence of these compounds in surface waters receiving wastewater 
effluents, but limited information is known about the presence of these compounds during 
drinking water treatment when contaminated surface waters are used as source water. 
1.4 Presence of Pharmaceuticals in Drinking Water Supplies 
Globally, there have been few studies that have investigated the presence of 
pharmaceuticals in full scale drinking water treatment systems (Zuccato et al., 2000; 
Redderson et al., 2002; Boyd et al., 2003; Stackelberg et al., 2004; Hernando et al., 2006; Hua 
et al. 2006a; Hummel et al., 2006; Kim et al., 2006; Vanderford and Snyder, 2006), and few 
compounds have been reported in drinking water samples.   
Zuccato et al. (2000) reported concentrations of tylosin, clofibric acid and diazepam in 
drinking water samples collected from three water systems in Italy, with the highest 
concentration reported for diazepam at 23.5 ng/L. Hummel et al. (2006) reported maximum 
concentrations of 20 ng/L of carbamazepine in drinking water samples collected from three 
conventional water treatment facilities in Germany. Carbamazepine was also reported in 
drinking water samples collected in water treatment facilities in Canada (Hua et al., 2006a) 
and South Korea (Kim et al., 2006).  Hua et al. (2006a) reported low concentrations of 
carbamazepine in finished water collected from a water treatment facility in Windsor, Ontario 
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with mean concentrations of 2 ng/L or below for water not treated with ozone and non-
detectable levels for water treated with ozone.  
In the United States, ibuprofen was detected in two out of fifteen finished drinking 
water samples collected from water treatment facilities in Southern California, with a 
maximum concentration of ibuprofen at 1.25 µg/L (Loraine and Pettigrove, 2006).  Boyd et 
al. (2003) investigated the presence of a number of pharmaceuticals in drinking water 
treatment facilities located in Ontario, Canada and Louisiana, USA.  Water samples were 
collected at different locations along the treatment processes at each facility.  Naproxen was 
one of the few compounds detected in the surface water samples and was not detected in any 
of the finished water samples collected at the water treatment facilities investigated.  
Stackelberg et al. (2004) investigated the presence of a number of organic contaminants in 
surface water and treated water samples collected from a conventional water treatment facility 
in the United States.  A total of seventeen contaminants were detected in the finished drinking 
water samples, and four were prescription and non-prescription drugs.  Carbamazepine was 
one of the compounds detected in the finished drinking water at a maximum concentration of 
258 ng/L.  
Tauber et al. (2003) investigated the presence of acidic and neutral pharmaceuticals 
and antibiotics in drinking water treatment facilities in ten Canadian cities.  Carbamazepine 
and gemfibrozil were the only two compounds detected in finished drinking water samples. 
Carbamazepine was detected in water treatment facilities located in three cities at 
concentrations of 6.5, 8.4 and 24 ng/L.  Gemfibrozil was detected in only water treatment 
facility at a concentration of 70 ng/L.  Although, this report was not peer-reviewed and was 
conducted by two Canadian media sources, it indicates that current water treatment 
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technologies being employed in Canadian cities are not effectively reducing these compounds 
from drinking water supplies.  
Servos et al. (2007) investigated the presence of acidic drugs in surface water and 
treated water samples collected from drinking water facilities in Ontario, Canada. Naproxen, 
gemfibrozil, and ibuprofen were detected at the highest concentrations in the surface water 
samples, with concentrations in the low ng/L range.  Ibuprofen was one of the few compounds 
detected in the treated water samples and showed minimal reduction during water treatment. 
There have also been very few studies that have monitored the presence of 
pharmaceuticals in groundwater wells used for drinking water production.  Gemfibrozil and 
ibuprofen were not detected in the groundwater monitoring wells used for water recharge 
purposes (Drewes et al., 2002).  However, carbamazepine was present in two monitoring 
wells at concentrations of 455 ng/L and 610 ng/L, and naproxen was detected at 20 ng/L in 
one of the wells (Drewes et al., 2002).  Sacher et al. (2001) detected the presence of 
carbamazepine (maximum concentration of 900 ng/L) and sulfamethoxazole (maximum 
concentration of 410 ng/L) during a groundwater monitoring study in Germany, in which 105 
samples were collected.  Carbamazepine was detected in 13 samples and sulfamethoxazole 
was detected in 11 samples.  Carbamazepine and ibuprofen have also been detected in 
groundwater samples collected in France at concentrations of 13.9 and 43.2 ng/L and 0.2 and 
0.6 ng/L, respectively (Rabiet et al., 2006). 
Heberer (2002a) summarized results from previous studies that had investigated the 
presence of pharmaceuticals in different matrices in Germany, including groundwater wells 
and drinking water samples.  Gemfibrozil and ibuprofen were the only compounds detected in 
groundwater wells at concentrations of 340 ng/L and 200 ng/L, respectively. 
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1.5 Drinking Water Treatment Processes 
The ability to reduce the concentrations of pharmaceuticals during wastewater and 
water treatment has been the focus of many research efforts (Zwiener, 2007).  Numerous 
studies have shown that current wastewater treatment technologies, and to a lesser extent 
water treatment processes, are not eliminating these compounds from entering surface waters 
and drinking water supplies (Ternes, 1998; Thomas and Foster, 2005; Castiglioni et al., 2006).  
The current conventional technologies (coagulation, flocculation and sedimentation) were not 
designed to remove emerging contaminants, like PPCPs, therefore more advanced treatments 
have been developed and applied to see if they are capable of reducing these compounds 
(Ternes et al., 2002; Ternes et al., 2003; Vieno et al., 2005). The application of ozonation, 
advanced oxidation processes (AOPs), membrane technologies and filtration devices have 
proven to be effective in reducing some pharmaceuticals present in wastewater and water 
(Zwiener and Frimmel, 2000; Ternes et al., 2001; Ternes et al., 2002; Huber et al., 2003; 
Ternes et al., 2003; Khan et al., 2004; Vogna et al., 2004; Huber et al., 2005a; Huber et al., 
2005b; Nghiem et al., 2005; Vieno et al., 2005; Westerhoff et al., 2005; Hua et al., 2006b; 
Radjenovic et al., 2007).  
1.6 Objectives of Thesis 
 The purpose of this thesis project was to identify and quantify the presence of 
pharmaceuticals in Canadian drinking water supplies, and to provide information to assess the 
implications of these compounds on drinking water quality.  It has been well established that 
these compounds are present in wastewater effluents and surface waters in Canada, but 
minimal information is known about their presence in drinking water supplies and the 
effectiveness of current water treatment processes in reducing these compounds.    
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The first objective of this thesis was to investigate the presence of a selected number 
of human and veterinary pharmaceuticals in water samples collected from two large 
municipal full scale water treatment facilities and groundwater systems in a susceptible 
Southern Ontario watershed.  The second objective was to investigate the seasonal variability 
of these compounds in surface water and drinking water, and the third objective was to 
determine how effective two water treatment facilities were in reducing pharmaceuticals 
during drinking water production. 
Surface water (raw water) and treated water samples were collected from two drinking 
water systems over a 12 month period to investigate the seasonal changes in the compounds 
and concentrations detected.  The two treatment facilities were selected based on their relative 
position in the watershed and application of different treatment technologies used.  Both 
facilities used conventional treatment technologies, but one of the selected water treatment 
facilities had advanced treatment with ozonation, granular activated carbon (GAC) filters and 
ultra-violet irradiation.  Comparisons were made in the ability of the facilities to reduce the 
concentrations of these contaminants to non-detectable levels. All of the water samples 
collected were extracted using solid phase extraction (SPE) techniques and were analyzed by 
liquid chromatography with electrospray ionization tandem mass spectrometry (LC-ESI-
MS/MS).  
 This thesis supports the international effort to evaluate the risk of these emerging 
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 This study investigates the use of solid phase extraction (SPE) techniques and liquid 
chromatography with electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS) in 
determining the presence of selected pharmaceuticals in environmental matrices.  The 
analytical method was applied to surface water (raw water) and treated water samples 
collected from two drinking water treatment facilities in Southern Ontario over a 12 month 
period, and raw water samples collected from eight groundwater wells. Three different 
quantification approaches were applied, and the estimated final concentrations were compared 
to determine the extent of how matrix components can impact the signal response. The results 
illustrate that compounds analyzed in negative ionization mode are impacted by the matrix to 
a greater extent compared to compounds analyzed in positive ionization mode.  However, 
seasonal trends remained similar among the different quantification methods.  The 
compounds detected in the water samples, using the analytical method, represent a variety of 
therapeutic classes including human and veterinary antibiotics, anti-inflammatory agents, and 
lipid regulating drugs. The concentration range varied from below 6 ng/L for gemfibrozil to 
close to 1 µg/L for carbamazepine. Failure to recognize the impact of matrix effects on the 
analysis can lead to major errors in quantification.  These effects are dependent on the matrix, 
the methodologies, and the properties of the analyte. This study illustrates the importance of 
addressing matrix effects in order to report reliable data to be used in assessing the potential 
risks of these environmental contaminants on environmental and human health. 
2.2 Introduction 
In recent years, the use of liquid chromatography and mass spectrometry has become 
routine instrumentation for determining the presence of a wide variety of pharmaceuticals in 
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the environment (Zwiener and Frimmel, 2004; Richardson and Ternes, 2005).  The 
development of ionization interfaces, which act as a connection between liquid 
chromatography and mass spectrometry, has allowed for the direct introduction of analytes 
from the separation column into the high vacuum mass spectrometer (Rossi and Sinz, 2002).  
Electrospray ionization (ESI) and atmospheric pressure chemical ionization (APCI) are 
commonly applied ionization sources used in helping to determine the presence of 
pharmaceuticals and personal care products in environment matrices.  One of the 
disadvantages of using ESI, and to a lesser extent APCI, is the susceptible to matrix effects. It 
has been suggested that the actual ionization mechanism of how ions are created in solution 
phase of the ESI interface is responsible for matrix effects observed (Hernando et al., 2004; 
Bos et al., 2006).  The exact mechanism of how the co-eluting matrix components interfere 
during the ESI process is not clear, but involves the mechanisms of how ESI produces gas 
phase ions (Kloepfer et al., 2005).  Signal suppression or enhancement are attributed to matrix 
components that co-elute from the LC column at the same time as the analytes, and as a result 
enter the ionization source at the same time, where ionization efficiency of the analyte is 
impacted by the presence of matrix components (Kloepfer et al., 2005; Gómez et al., 2006; 
Hummel et al., 2006; Van De Steene et al., 2006; Vieno et al., 2006).  This situation creates 
the possibility of the analyte and matrix interacting with each other during ionization, and in 
most cases ionization of the analyte being suppressed.  The end result is inaccurate final 
concentrations being reported because matrix effects have not been addressed during method 
development.  There have been a number of recent published studies that have used only a 
limited number of internal standards to quantify the analytes without careful consideration of 
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potential matrix effects (Hirsch et al., 1998; Castiglioni et al., 2004; Bendz et al., 2005; 
Castiglioni et al., 2005; Hao et al., 2006; Lissemore et al., 2006). 
Research has started to investigate and summarize possible solutions for addressing 
matrix effects, when using LC-ESI-MS/MS instrumentation (Hernando et al., 2004; Gómez et 
al., 2006; Hua et al., 2006b; Hummel et al., 2006).  Possible solutions have included 
improvements in sample extraction and clean-up procedures (Zrostlíková et al., 2002; 
Hernando et al., 2004; Kloepfer et al., 2005; Stoob et al., 2005; Van De Steene et al., 2006); 
decreasing the injection volume into the LC, in which a reduced amount of matrix enters the 
LC column at one time (Hernando et al., 2004; Hua et al., 2006b), changing operational 
parameters of the instrument (i.e. decreasing flow rates into the ionization source) (Choi et al., 
2001; Zrostlíková et al., 2002; Kloepfer et al., 2005; Van De Steene et al., 2006) or applying 
alternate quantification methods (i.e. standard addition and internal standard/surrogate 
standard calibration methods), which makes use of standards being added during sample 
extraction and analysis, to correctly quantify compounds in environmental matrices 
(Richardson and Ternes, 2005).  
The standard addition approach has been used extensively to quantify concentrations 
of pharmaceuticals in different matrices and correct for potential matrix effects (Lindsey et 
al., 2001; Zrostlíková et al., 2002; Metcalfe et al., 2003a; Gómez et al., 2006; Hernando et al., 
2006).  The main disadvantage of this calibration approach is it tends to be labour intensive 
and time consuming because different calibration curves have to be prepared for each matrix 
type (i.e. soil, sediment, surface water, sewage effluent) and for different compositions within 
each matrix type (Miao and Metcalfe, 2003; Van De Steene et al., 2006).   
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Standard addition or the matrix-matched calibration approach has been commonly 
used by researchers looking at the presence of acidic and neutral pharmaceuticals, statin drugs 
and various antibiotics in surface water samples and wastewater samples collected in Canada 
(Miao et al., 2002; Metcalfe et al., 2003a; Metcalfe et al., 2003b; Miao et al., 2004; Miao et 
al., 2005). The standard addition approach has also been conducted in determining the 
presence of selected pharmaceuticals in environmental samples collected in United States and 
Europe (Sacher et al., 2001; Kolpin et al., 2002; Löffler and Ternes, 2003; Hernando et al., 
2004; Hernando et al., 2006). 
 The internal standard calibration method is another common approach for quantifying 
the presence of pharmaceuticals and other organic compounds in environmental matrices, and 
at the same time addressing potential matrix effects (Hua et al., 2006b; Hummel et al., 2006; 
Van De Steene et al., 2006; Vieno et al., 2006).  The use of internal standards, either 
isotopically labeled internal standards (deuterated surrogates or 13C-labeled standards) or 
structural analogues, have been used to investigate the presence of a number of human and 
veterinary medicines in environmental matrices (Hilton and Thomas, 2003; Löffler and 
Ternes., 2003; Vanderford et al. 2003; Cahill et al., 2004; Lindberg et al., 2004; Stoob et al., 
2005; Hernando et al., 2006; Hummel et al., 2006).   
The best internal standard is an isotopically labeled standard (13C-labeled compounds 
or deuterated compounds).  These standards have similar evaporation properties and would go 
through the same degree of signal suppression or enhancement in the matrix as the analyte of 
interest (Hernando et al., 2006; Van De Steene et al., 2006).  Recently, the use of isotopically 
labeled standards have been used for quantification of selected pharmaceuticals in drinking 
water, surface water and wastewater samples collected in Canada (Hua et al., 2006a; Hua et 
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al., 2006b), the United States (Vanderford and Snyder, 2006) and Germany (Hummel et al., 
2006).    
One of the disadvantages of using an internal standard calibration approach is that 
these internal standards, isotopically labeled surrogates, are sometimes not available 
commercially and can be expensive.  In addition, if structural analogues are used as internal 
standards, it is difficult to find a compound that is structurally similar to the analytes of 
interest and not already present in environmental matrices (Van De Steene et al., 2006).   
This study critically assesses a LC-ESI-MS/MS analytical method for determining the 
presence of selected pharmaceuticals in water samples used in previous studies (Hao et al., 
2006; Lissemore et al., 2006).  Three quantification methods were applied in this study which 
include an external solvent calibration approach, and two internal standard calibration 
approaches, one involving the use of deuterated surrogates (isotopically labeled standards) 
and the other using a 13C-labeled compound (13C6-sulfamethazine phenyl). The analytical 
method was applied to surface water (raw water) and treated water samples collected from 
two full scale drinking water systems in a Southern Ontario watershed.  The field samples 
were used to determine the effectiveness of the analytical method and the limitations 
associated with using different quantification approaches for addressing potential matrix 
effects. 
2.3 Materials and Methods 
2.3.1 Chemicals and Standards 
Most pharmaceutical standards were purchased from Sigma-Aldrich (St. Louis, MO, 
USA), along with ammonium hydroxide (ACS reagent grade), heptafluorobutyric acid 
(HFBA), and ethylenediaminetetraacetic acid (EDTA) disodium salt dehydrate (ACS reagent 
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grade). Clofibric acid and 4-acetamidophenol were purchased from Aldrich Chemical 
Company (Milwaukee, WI, USA), lasalocid A sodium salt was purchased from Riedel-de 
Haën (Seelze, Germany), and ammonium acetate (above 99% purity) was purchased from 
Fluka Chemika (Mississauga, ON, Canada). Sulfamethazine-phenyl-13C6 (13C-90%) was 
purchased from Cambridge Isotope Laboratories Inc. (Andover, MA, USA).  The deuterated 
surrogates, carbamazepine-D10 (98.2 atom %D), gemfibrozil-D6 (2,2-dimethyl-D6, 99.7 atom 
%D), diclofenac-D4 (phenyl-D4, 92.5 atom%D), (+)-ibuprofen-D3 (α-methyl-D3, 99.4 atom 
%D) and N-(4-hydroxy-2,3,5,6-D4) acetamide (4-acetamidophenol-D4, 99.4 atom %D), were 
purchased from CDN Isotopes (Pointe-Claire, PQ, Canada).  Methanol (distilled in glass), 
acetone (HPLC grade), acetronitrile (HPLC grade), water (HPLC grade) and sulphuric acid 
were purchased from Caledon Laboratories Ltd. (Georgetown, ON, Canada), and sodium 
hydroxide pellets (ACS reagent grade) were purchased from J.T. Baker Inc. (Phillipsburg, NJ, 
USA) for preparation of a 5% sodium hydroxide solution (w/v) in nanopure water. A 
Barnstead NANOpure DiamondTM water purification system was used to provide nanopure 
water for sample preparation and extraction.   
2.3.2 Preparation of Solutions 
Stock solutions of all analytes, the deuterated surrogates and 13C6-sulfamethazine 
phenyl were prepared by weighing out approximately 10 mg of the powdered neat standard 
and dissolving the contents with a dilution solvent.  Most of the stock solutions were diluted 
with methanol, however, based on solubility; acetone, mixtures of methanol and water and 
mixtures of methanol and acetone were used.  The concentration of the stock solutions was 
approximately 1 mg/mL. The stock solutions were used to prepare spiking solutions, 
calibration standards, control standards, the internal standard solution, and the mixed 
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surrogate standard solution containing the deuterated surrogates. The control standards were 
used to determine relative recovery rates for the spiked analytes and consisted of a known 
volume of the spiking solutions. The calibration standards (6 to 7 calibration points) consisted 
of known concentrations of the analytes in a solvent solution. The internal standard solution 
consisted of 13C6-sulfamethazine-phenyl in nanopure water, and was used for quantification 
and to correct for volume injection problems.  The mixed surrogate standard solution 
consisted of the five deuterated surrogates including, D10-carbamazepine, D6-gemfibrozil, D4-
diclofenac, D4-4-acetamidophenol and D3-ibuprofen.  The deuterated compounds monitored 
method performance and extraction efficiency. All standard solutions were stored at -20 °C 
except the internal standard solution, which was stored at 4°C.   
2.3.3 Study Sites 
 Description of Drinking Water Treatment Facilities 
 Two large residential municipal drinking water treatment facilities were selected for 
this project, Facility A and Facility B.  These facilities were selected based on previous data 
collected, differences between treatment processes used, raw water source and location within 
the watershed. Both of the facilities use river water as their raw water source and are located 
within the same watershed in Southern Ontario. 
 This particular watershed is one of the largest in Southern Ontario with a drainage area 
of 6,965 km2. This watershed was selected due to its susceptibility of contamination from the 
26 municipal wastewater treatment facilities discharging into waterways, and approximately 
76% of the land being used for agricultural practices.  There are approximately 900,000 
people that live in this watershed, with the population steadily increasing.  The increase in 
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population growth and urbanization together with agricultural stressors will put pressure on 
the finite water resources of this area. 
Facility B is located downstream of Facility A, with an additional eleven wastewater 
treatment facilities located upstream of Facility B.  Figure 2.1 shows the locations of the 
drinking water treatment facilities relative to each other and to the wastewater treatment 
facilities within the watershed.  
Facility A is considered to be a full conventional water treatment facility and has a 
dual treatment system.  In addition to coagulation, flocculation, sedimentation, filtration, 
chlorination and chloramination processes; ozonation, GAC filters and ultra-violet (UV) 
irradiation are also present at this facility.   
Facility A receives their surface water from a low lift pumping station next to the 
river.  The water from the station is pumped to two reservoirs, where it is stored for a few 
days. The two reservoirs can hold up to 0.15 million cubic metres of water.  The storage of the 
surface water in the reservoir reduces the turbidity in the water and provides more consistent 
source water characteristics before it enters the actual treatment facility.  The storage reservoir 
also provides another control mechanism over the water collected from the river.  After a few 
days, water from the reservoir is pumped to surface water terminal storage units, which are 
located next to the treatment facility.  The water from these units can then flow by gravity into 
the facility and enters the treatment system. 
 Once the water reaches the treatment facility, it enters rapid mixing tanks, where a 
coagulant (i.e. polyaluminum chloride) is added.  Polyaluminum chloride helps to destabilize 
or entrap suspended particulate matter to allow the formation of settling aggregates.  The 











Figure 2.1: Schematic diagram of the locations of the two drinking water treatment 
facilities and wastewater treatment facilities in a Southern Ontario watershed 
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destabilization of particles and impurities, and allows for agglomeration. The next step in the 
treatment process is flocculation.  A polyelectrolyte agent (a polymer) is added at this point 
and helps to agglomerate suspended or very fine particles to form larger particles.  Gentle 
mixing also promotes collisions of the clumps to allow larger flocs to form.  The next step is 
sedimentation, in which floc particles formed in the previous step pass through a series of 
plates.  The particles can settle on the plates and then drop to the bottom of the settling basin.  
Once the large particles have been removed in the sedimentation process, water enters the 
ozone contactor tanks.  Liquid ozone is added to react and neutralize taste, odour and colour, 
and can also be used as a disinfecting agent.  For this particular facility, ozone is mainly used 
for taste and odour control. The next step is filtration, in which the water is passed through 
dual media filters to remove fine suspended particulate and organic matter.  This is completed 
by chemical and physical processes in the filters. The filters used at this facility consist of 
granular activated carbon (GAC) and sand.   
After the water has been filtered, it passes into the ultra-violet (UV) irradiation system. 
UV irradiation is considered the primary disinfection step at this particular facility.  At this 
facility ozone and UV are not added together and therefore this treatment is not considered an 
advanced oxidation process.   
Once the water leaves the UV system it is chlorinated using chlorine gas.  Chlorination 
occurs before the water is blended with groundwater sources from nearby wells.  Chlorine gas 
and anhydrous ammonia, for chloramination, are both used for disinfection purposes and 
provide residual levels of disinfection for the distribution system. Anhydrous ammonia is 
added just before water enters the distribution system (i.e. anhydrous ammonia is added after 
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the water from the facility is blended with water from the groundwater wells).  For back-up 
purposes, 20% liquid ammonium sulphate can be injected in case the anhydrous ammonia 
system is not working properly.  This facility, along with the nearby groundwater systems 
serves a population close to 200,000 people.  The facility produces about 20% of the potable 
water in the area, the rest of the potable water comes from groundwater sources. 
 Facility B is the second facility selected for this project and is considered a full 
conventional drinking water treatment facility.  The treatment processes include screening, 
coagulation, flocculation (sand ballasted flocculation), sedimentation, chlorination, filtration, 
chloramination and fluoridation.   
The treatment process begins by pumping water from the river into the screening 
house.  After large objects have been removed using coarse screens, the water is pumped to 
the pretreatment system building. Powdered activated carbon (PAC), certified NSF 61, is the 
first chemical added in the two pipes that feed the dual/mirror pretreatment system. 
Approximately one foot downstream of PAC addition is the location of where activated silica 
enters the treatment process, and where coagulation begins.  Activated silica (an inorganic 
polymer) is produced by the reaction of sodium silicate and sulphuric acid.  Activated silica is 
a coagulant aid that is usually added after the addition of the coagulant.  However, this 
coagulant aid is sometimes added upstream of where the coagulant is added.  The reason for 
this is that during cold water conditions, lower pretreatment turbidities are achieved if the 
activated silica is added upstream of where the coagulant is added.  During the summer 
months, the location of the activated silica will not have an affect on the performance of the 
coagulant. At the inlet of the coagulant tank, polyaluminum sulphate hydroxide chloride 
(SternPac 50) is added which is the coagulant used in this facility.  The coagulant and 
 27
activated silica are added to help with the destabilization of large particles and the formation 
of aggregates.  The next step is sand ballasted flocculation (ActifloTM), in which a certain 
flocculation aid (Ciba’s Magnafloc LT 27AG) is added to agglomerate fine particles and form 
larger particles or flocs.  The flocculation aid helps bind the microsand (weighing agent) to 
the flocs, so the large particles/flocs can settle down and be removed.  Two important feature 
of the sand ballasted flocculation system is that the settling plates in the actual sedimentation 
tanks increases the surface area for flocs settling out and the sand used can be recycled during 
treatment by separating it from the sludge with hydrocyclones. If LT 27AG was not added, 
the sand and flocs would not stick together, and the settling out of particles would be minimal. 
Once the water has left the sedimentation tanks, a concentrated chlorine solution 
enters the two chlorine contact chambers.  In other words, chlorine gas is not bubbled in the 
chlorine contact chambers. The two chambers are designed to provide a T10 (time required for 
10% of the water to pass through the chlorine contact chambers) of 23 minutes at a flow rate 
of 100 ML/day. The concentrated chlorine solution is prepared by mixing chlorine gas and 
water in the chlorinators.  After chlorination, a concentrated ammonia solution is added at the 
outlet of the chlorine contact chambers for secondary disinfection.  Ammoniators are used to 
mix ammonia gas and water to make a concentrated ammonia solution. In cold water 
conditions, the concentrated ammonia solution is added at the inlet of the high lift (after the 
treated water reservoirs). This increases the free chlorine contact time (hours at 100ML/day) 
and maintains the require chlorine residual at the point of entry into the distribution system. 
After disinfection, the water is filtered by 5 filters, in which 3 of them are paired.  The 
filters consist of 0.45 metre of sand and 0.45 metre of anthracite coal.  Once the water has 
passed through the filters, fluoridation takes place.  Sodium silicofluoride is added to the 
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water before it enters one of two on-site storage reservoirs for holding treated water.  Fluoride 
is added to the treated water to help prevent tooth decay for the population it serves.  This 
facility supplies drinking water to a city with a population of 93,000 and a smaller community 
which has a population of 5,000.  The facility is designed to treat 100ML/day, but is restricted 
by the filters to treat no more than 80ML/day. 
At both facilities, chloramination (addition of ammonia) takes place to convert free 
chlorine to the combined form, which is a more stable disinfectant for maintaining chlorine 
residuals throughout the distribution system. 
Water Sample Collection at Drinking Water Treatment Facilities 
Two sampling locations were selected at each facility, a raw water location and a 
treated water location.  All raw water samples were collected before any treatment processes 
had occurred, and all treated water samples were collected prior to the point of entry into the 
distribution system. It should be stated that the collection of the raw and treated water samples 
did not account for retention time within the treatment facilities. 
Water samples were collected for pharmaceutical analysis, as well as water chemistry 
parameters.  Due to the analytical and sample collection requirements for these analyses, 
separate water samples had to be collected for each analysis at all sampling locations. 
For Facility A, the raw water samples were collected at low lift pumping station, 
which is located next to the river.  This sampling location is situated before the water enters 
the storage reservoir and is the one of the sites used by the Ontario Ministry of the 
Environment for their monitoring programs. The treated water samples were collected after 
chlorination but prior to the water being blended with the groundwater and anhydrous 
ammonia being added.  This sampling site was selected because it represented the water 
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produced from the treatment processes located at Facility A. This sampling site was not a 
sampling location used by the Ontario Ministry of the Environment for their programs, but 
met the criteria for a representative sampling location.  
For Facility B, the raw water samples could not be collected at the screening house 
because there was no appropriate sampling site.  The surface water intake pipe where the raw 
samples are usually collected is located a bit further down the river from the screening house.  
This should not be a concern considering this part of the river tends to have a long retention 
time and studies completed by the facility have shown similar source water characteristics are 
present at the screening house compared to the surface water intake pipe at the raw water 
sampling location.  The treated water samples were collected just before the water entered the 
distribution system.  Both sampling locations at this facility are used by the Ontario Ministry 
of the Environment for their monitoring programs. 
Sample Collection 
Water samples were collected at each sampling location at both facilities on the first 
Tuesday of each month from April 2005 to March 2006 for water chemistry parameters and 
pharmaceutical analysis.  The only exception was November 2005, in which samples were 
collected on Tuesday November 15th 2005 from both facilities. In addition, water samples 
collected in January, February and March 2006 for water chemistry parameters were not 
analyzed due to the laboratories being renovated.  
Water samples were collected at Facility A between 10:00 a.m. to 12:00 p.m. and 
water samples were collected at Facility B between 1:00 p.m. and 2:30 p.m. on sample 
collection days.   
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Duplicate grab water samples were collected for pharmaceutical analysis in one litre 
pre-cleaned amber glass bottles with Teflon-lined caps (ProClean glass bottles) from Systems 
Plus (Baden, ON, Canada).  These glass bottles were precleaned with laboratory-grade 
phosphate-free detergent wash, rinsed with acid, rinsed three times with reverse osmosis 
water, oven dried at 300°C for three hours, capped with a Teflon-lined lid and packed under 
quality controlled conditions. These bottles were not rinsed and were filled to the shoulder of 
the bottle.  Approximately, 30 to 45 drops of a preservative, sodium thiosulphate 25% (w/v), 
was added to all water samples.  The bottle was shaken to mix the contents. The preservative 
was added to quench the chlorine present in the sample.  Previous preliminary data showed 
that the present of chlorine in the samples was impacting the signal response of certain 
analytes. Although no chlorine would be present in the raw water samples, sodium 
thiosulphate was added to maintain consistency between all samples collected for this type of 
analysis. The bottles were place in a cooler with ice packs to keep the temperature of the 
samples between 4 to 10°C during transportation. The samples were place into a fridge with a 
temperature of approximately 4 to 8°C until transported to the laboratory for sample 
preparation, extraction and analysis.   
For general water chemistry parameters, water samples were collected in 500 mL clear 
plastic bottles with white lids, with only one sample from each site being extracted and 
analyzed.  The lids and bottles were rinsed three times and then filled to the top.  For these 
samples, no preservatives were added.  The bottles were placed in the same cooler as the 
samples collected for pharmaceutical analysis. A total of 164 water samples were extracted 
and analyzed for pharmaceuticals and 43 water samples were analyzed for water chemistry 
parameters. 
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On sample collection days, general monitoring data was recorded, including daily flow 
rates, retention time and chemical dosages.  Temperature, pH and turbidity were also recorded 
for the water samples as well as free chlorine, combined chlorine and total chlorine levels for 
the treated water samples. 
Description of the GUDI Well Locations 
 
In addition to water samples being collected from two drinking water treatment 
facilities, water samples were also collected from groundwater wells.  Two deep groundwater 
reference wells (Well C and Well D) and six susceptible groundwater wells under the direct 
influence of surface water (referred to as GUDI) (Well A, Well B, Well E to H) were 
investigated for this study.  The susceptible GUDI wells were selected based on monitoring 
data collected by the Municipality (i.e. the presence of E. coli bacteria and fecal coliforms), 
potential sources of contamination and proximity to surface water.  According to the Safe 
Drinking Water Act, 2002, Ontario Regulation 170/03 (Drinking-Water Systems), GUDI 
systems (groundwater under the direct influence of surface water) are defined in Section 2 (1-
4). The susceptible GUDI wells for this project were selected based on the definitions outlined 
in Section 2.2.2 in which a drinking water system obtains water from an infiltration gallery 
and Section 2.2.6 in which the drinking water system exhibits evidence of contamination by 
surface water (Government of Ontario, 2003). 
All eight wells were located in the same watershed as the two drinking water treatment 
facilities, and each well was visited prior to sample collection to ensure the sampling location 
met the criteria for a representative sampling location. These wells had on-line monitoring 
analyzers for turbidity, pH, temperature and free chlorine levels.  For the most part, UV 
irradiation, chlorination and chloramination were used for disinfection purposes.  
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 Most of the susceptible GUDI wells were located in rural areas, with the exception of 
Well G, which was located in an urban area. Well A and Well B were both located in small 
rural communities and found near surface waters. Well E and Well F were located close to 
each other and to a small creek.  Both of these wells were partly surrounded by agricultural 
fields. Well G was located in an undeveloped flood plain of the river and close to a new 
housing development.  Well H was located in a small rural community and consisted of 4 
submersed wells which formed an infiltration gallery and fed a common header.  Well H was 
also located downstream of a seasonal trailer park (i.e. source of potential contamination), and 
about 30 feet from the river bed (i.e. in the flood plain of the river).  Three of the four wells 
were only 3 metres deep and the other one was 2.6 metres deep. 
Water Sample Collection at GUDI Well Locations 
In contrast to the water samples collected at the two drinking water treatment 
facilities, only raw water samples were collected from each well.  All raw water samples were 
collected before any treatment processes had occurred at the well locations. 
Water samples were collected for pharmaceutical analysis, as well as water chemistry 
parameters.  Due to the analytical and sampling collection requirements for these analyses 
outlined by the Ontario Ministry of the Environment, separate water samples had to be 
collected for each type of analysis at all sampling locations. 
Sample Collection 
Duplicate grab raw water samples were collected from each well location on Tuesday 
September 27th 2005 and again on Tuesday October 11th 2005 for pharmaceutical and water 
chemistry analysis.  One of the reasons for taking samples during the fall season was to 
capture time periods when these susceptible wells would be under the greatest impact of 
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potential contamination, with the spreading of livestock manure and biosolids to agricultural 
land, and changes in water quality and water quantity parameters.  Raw water samples were 
collected at all eight well locations between 9:00 a.m. and 2:30 p.m. on sample collection day.  
A total of 32 raw water samples were collected and analyzed for pharmaceuticals, and 16 
samples were analyzed for water chemistry parameters.   
The raw water samples for the GUDI study were collected in a similar way as 
described for the collection of water samples at the drinking water treatment facilities. 
2.3.4 Sample Analysis – Water Chemistry Parameters 
 Water samples collected for general water chemistry parameters were transported in 
coolers at approximately 4°C to 10°C, and extracted within 10 days of being submitted to the 
licensed Ontario Ministry of the Environment Laboratory in Etobicoke, Ontario.  A number of 
different analytical methods were used to determine the general water chemistry parameters 
(Ontario Ministry of the Environment Laboratory Services Branch, 2005).  Colourimetry 
techniques were used to determine the presence of chloride, true colour, ammonium nitrogen, 
nitrite nitrogen, nitrite plus nitrate nitrogen, reactive phosphate, total kjeldahl nitrogen, total 
phosphate, molybdate reactive silicates and dissolved carbon. Sulphates and fluoride 
concentrations were determined by automated ion chromatography, and the amount of solids 
present was determined by gravimetry techniques.  Atomic absorption spectrophotometry was 
used to determine the presence of cations in the water samples, and conductivity, pH, and 
alkalinity were determined by potentiometry techniques.  The turbidity of the water was 




2.3.5 Sample Analysis – Pharmaceuticals 
Sample Preparation 
 The water samples collected for pharmaceutical analysis were transported in coolers at 
temperatures between 4°C and 10°C to the laboratory.  The samples were extracted within 24 
to 36 hours of being collected.  
Before sample preparation began, the water samples were allowed to warm up to room 
temperature.  A sample volume of 400 mL was measured out and transferred into a 1 L 
precleaned glass amber bottle with a Teflon-lined cap.   In addition to the field water samples 
being prepared, three 1 L precleaned glass amber bottles with 400 mL of nanopure water were 
also prepared.  One of the three bottles was used as a blank sample and the other two bottles 
were used for spiked nanopure water samples for quality control and quality assurance 
(QC/QA).  Sodium thiosulphate 25% (w/v) was added as a preservative to both the blank and 
spiked samples.  This was done to maintain the consistency of how the field samples were 
prepared.  Approximately 15 to 23 drops of sodium thiosulphate was added to the blank and 
spiked samples. For the field water samples, no further sodium thiosulphate was added as the 
preservative was already added at the time of collection. 
 For all field water samples and the blank sample, 0.5 mL of the mixed surrogate 
standard solution was added to each bottle.  For the two spiked samples, 0.5 mL of spiking 
solutions and 0.5 mL of the mixed surrogate standard solution was added.  The spiking 
solutions consisted of known concentrations of all analytes.  Approximately, 2 g of EDTA, a 
chelating agent, was added to the sample bottles.  The samples were placed on a roller for 10 
to 15 minutes to help dissolve EDTA.  After EDTA was dissolved, 10 mL of 0.25 M 
ammonium acetate solution was added to each bottle as a buffer.  The bottles were shaken and 
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the pH of the all samples was adjusted to 6.95 ± 0.05.  The pH of the sample was adjusted 
using a solution of 5% (w/v) sodium hydroxide in nanopure water to increase the pH or a 10% 
(v/v) solution of sulphuric acid (H2SO4) was added to lower the pH.  The final pH for each 
sample was recorded.   
Sample Extraction  
The water samples were extracted using solid phase techniques.  The goal of this 
technique was to clean-up and pre-concentrate the water samples for liquid chromatography 
and mass spectrometry analysis.  For each extraction set, a 12-port VisiprepTM vacuum 
manifold manufactured by Supelco Inc. (Bellefonte, PA, USA) and Waters Oasis® HLB 
cartridges (6cc, 200mg) (Milford, MA, USA) were used for extracting the samples.  The 
sorbent in the SPE cartridges consisted of a copolymer designed to have hydrophilic and 
hydrophobic properties, and therefore could be used to extract a board spectrum of 
compounds with different chemical and physical properties. The sorbent consisted of a 
copolymer of divinylbenzene and vinylpyrrolidone (Richardson and Ternes, 2005).   
Before the samples were extracted, the cartridges were preconditioned with 5 mL of 
nanopure water, followed by 5 mL of methanol and 5 mL of 5% (v/v) of ammonium 
hydroxide in methanol.  After the cartridges were conditioned, 5 mL of nanopure water was 
added to each cartridge to prevent the sorbent from drying.  During the conditioning process, 
the flow rate was approximately 5 mL/min. 
 Teflon tubing with dimensions of 3 mm inner diameter and 4 mm outer diameter and a 
length of 60 mm was precleaned in a mixture of methanol and nanopure water.  The Teflon 
tubing and adapters were purchased from Supelco Inc. (Bellefonte, PA, USA) and were used 
to introduce the sample into the SPE cartridges.  The free end (with the stainless steel weight) 
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of each Teflon tube was placed into a sample bottle.  The other end of the tube with the 
adapter was placed onto the top of the SPE cartridge.  Once the tubing was connected, the 
valves of the manifold were opened and the vacuum was turned on.  The individual valves of 
the vacuum manifold were adjusted to maintain a steady drip from each cartridge, with a flow 
rate of approximately 5 to 10 mL/min and a vacuum pressure not exceeding -20” Hg.  After 
the sample had gone through the cartridge, the cartridge was dried by applying the vacuum for 
additional 5 to 10 min.   
 A wash solution of 5% methanol in nanopure water (a volume of 5 mL) was added to 
each cartridge.  The washing solution was used to remove weakly bound impurities from the 
sorbent of the SPE cartridge.  The valves of the manifold were opened and the vacuum was 
applied to allow the wash solution to go through the cartridges.  In order to dry the cartridge 
as much as possible, the vacuum was left on for about 15 min.   
Sample Elution 
 Labeled 15 mL polypropylene sterile culture tubes were placed in the appropriate slots 
of the VisiprepTM collection rack.  The rack was placed into the manifold and the cover was 
placed on top.   
The contents bound to the sorbent of the cartridge were eluted with 5 mL of methanol.  
The vacuum was turn on to start the elution process, in which 1 mL was slowly eluted.  After 
1 mL had been eluted, the vacuum was turned off and methanol was allowed to sit in the 
cartridges for approximately 1 min.  The remaining methanol passed through the cartridge by 
gravity.  This elution process took approximately 15 minutes.  Once there were no more drops 
coming from the bottom of the cartridge, the vacuum was turned on slowly to aspirate the 
remaining methanol out the cartridges. The manifold cover was lifted and the collection rack 
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containing the tubes with the final extracts was removed.  Pasteur pipettes were used to mix 
the contents in each tube and 1 mL of each final extract was transferred to a clean 2 mL clear 
glass vial with PTFE/Sil/PTFE lined cap purchased from Life Science (Peterborough, ON, 
Canada). 
Sample Evaporation 
 The 1 mL extracts were evaporated using a gentle stream of nitrogen gas.  Nitrogen 
gas was produced by a nitrogen generator from Whatman Canada (Mississauga, ON, Canada), 
and was controlled by a regulator. For the samples collected from April 2005 to September 
2005, an in-house nitrogen gas evaporator apparatus was used to evaporate the samples to 
dryness.  For the remaining sampling months, a solvent evaporation system was used. The SE 
500 system from Dionex Canada Inc. (Oakville, ON, Canada) decreased the amount of time 
needed for evaporating the sample extracts.   
 In addition to the sample extracts being evaporated, calibration standards and control 
standards had to be evaporated for analysis.  The control standards were prepared by adding 
0.3 mL of the spiking solutions plus 0.3 mL of the spiking deuterated surrogate solution into a 
2 mL vial.  The standards were evaporated to dryness using nitrogen gas.  For the preparation 
of the calibration standards for analysis, 0.2 mL of each calibration standard along with 0.2 
mL of the spiking deuterated surrogate solution was added to each vial.  The contents were 
evaporated to dryness in a similar way as the sample extracts and control standards.  
 The final step before instrumentation analysis was reconstituting the evaporated 
samples and standards with the internal standard solution.  The amount of internal standard 
solution added to the vial was in portion to the volume that was evaporated.  For the sample 
extracts, 100 µL of the working internal standard solution was added to the vial, and for the 
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calibration standards 200 µL of the internal standard solution was added.  The purpose of the 
internal standard solution was to monitor and correct for possible sample injection problems 
into the instrument and to quantify the unknown concentrations in the field samples. 
 The evaporated contents in the vial were mixed with the internal standard solution 
using a Pasteur pipette and then the solution was placed into a glass vial insert (Life Science, 
Peterborough, ON, Canada) and recapped. The vials were placed into the freezer until 
analysis.  The samples were usually analyzed within one week of being extracted. 
2.3.6 LC-ESI-MS/MS Instrumentation 
 All samples were analyzed using a liquid chromatography with electrospray ionization 
tandem mass spectrometer (LC-ESI-MS/MS).  The analytes were separated by an Agilent 
Hewlett Packer 1100 Series liquid chromatograph system (Mississauga, ON, Canada), which 
consisted of a vacuum degasser, binary pump, column compartment and an autosampler. The 
Agilent autosampler was replaced with a CTC Analytics HTC PAL autosampler (LEAP 
Technologies, Carrboro, NC, USA) in May of 2005.  The new autosampler was used for the 
samples collected from May 2005 to March 2006.  The injection volume for April 2005 was 
15 µL, but was increased to 20 µL for the remaining sampling months when the new 
autosampler was installed. A ThermHyperSil Gold RP-C18 (2.0 mm × 100 mm, particle size 
of 3 µm) separation column was used for all analyses and maintained at room temperature.   
The analytes were detected using an Applied Biosystems/MDS Sciex 4000 Q Trap™ 
mass spectrometer with an electrospray ionization source interface (TurboIonSpray™). The 
4000 Q TrapTM mass spectrometer is a hybrid triple quadrupole and linear ion trap (LIT) 
instrument, in which the second mass analyzer or Q3 region can be operated as a standard 
quadrupole mass spectrometer or have the capability of being used as linear ion trap mass 
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spectrometer.  For this project, the Q3 region was operated as a quadrupole mass analyzer, 
and multiple reaction monitoring (MRM) was selected as the scan mode to quantify 
compounds present in the water samples. The mass spectrometer was operated with unit 
resolution for both mass analyzers.  
 The target pharmaceuticals investigated for the project were grouped according to 
analytical method used, and are summarized in Table 2.1. 
Analysis of Group A Pharmaceuticals 
The pharmaceuticals in Group A consisted of five tetracyclines, three 
fluoroquinolones, three macrolides, seven sulfonamides, two anti-inflammatory agents 
(ketoprofen and naproxen), carbamazepine, monensin sodium salt, penicillin G sodium salt, 
trimethoprim and tylosin tartrate. The compounds in Group A were analyzed with the 
electrospray ionization source operated in positive ionization mode.  The flow rate was 0.2 
mL/min and 0.03% heptafluorobutryic acid (HFBA) (mobile phase A) and 100% HPLC grade 
acetronitrile (mobile phase B) was used for the binary gradient elution.  The mobile phase 
gradient elution was as follows: at 0 min A/B was 85:15, at 13 min and 15 min A/B was 
0:100, at 17 min A/B was 85:15 and remained at this gradient until the end of the 28 min run.  
Details on the MRM ion transitions, collision energies and dwell times for analytes in Group 
A are summarized in Table 2.2. 
Analysis of Group B Pharmaceuticals 
The pharmaceuticals in Group B consist of three anti-inflammatory agents (ibuprofen, 
diclofenac sodium salt and indomethacin), two lipid regulating agents (bezafibrate and 
gemfibrozil), a metabolite of clofibrate (clofibric acid), 4-acetamidophenol, carbadox,  
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Table 2.1: List of pharmaceuticals (including deuterated surrogates and internal standard) 
evaluated in the water samples collected from two drinking water treatment 
facilities and groundwater wells over a 12 month period. 
 
Group A* Group B** 
Carbamazepine 4-Acetamidophenol 
Chlortetracycline HCl Bezafibrate 
Ciprofloxacin Carbadox 
Doxycycline HCl Chloramphenicol 
Enrofloxacin Clofibric acid 
Erythromycin Diclofenac sodium salt 
Ketoprofen Gemfibrozil 
Lincomycin HCl Ibuprofen 
Meclocycline sulfosalicylate salt Indomethacin 
Monensin sodium salt Lasalocid A 
Naproxen Sulfadiazine sodium salt 
Norfloxacin Warfarin, minimum 
Oxytetracycline HCl Virginiamycin M1 











Tylosin tartrate  
D10-Carbamazepinea  
13C6-Sulfamethazine phenylb  
*Group of pharmaceuticals analyzed in positive electrospray ionization mode 








Table 2.2: Multiple reaction monitoring (MRM) ion transitions, dwell time, and collision 
energy for each pharmaceutical of Group A. 
 







Carbamazepine 237 194 10 20 
Erythromycin 734 158 25 32 
Ketoprofen 255 105 20 20 
Lincomycin 
hydrochloride 407 126 25 32 
Naproxen 231 185 20 20 
Penicillin G sodium 
salt 335 176 25 25 
Roxithromycin 838 158 25 40 
Sulfachlorpyridazine 285 156 15 20 
Sulfadimethoxine 311 156 15 30 
Sulfamerazine 265 156 15 23 
Sulfamethazine 279 186 15 23 
Sulfamethizole 271 156 15 20 
Sulfamethoxazole 254 156 15 21 
Sulfathiazole 256 156 15 20 
Trimethoprim 291 123 10 30 
Tylosin tartrate 916 174 20 50 
13C6-Sulfamethazine 
phenyl 285 186 20 25 




chloramphenicol, lasalocid A, a sulfonamide (sulfadiazine sodium salt), an anti-coagulant 
agent (warfarin) and a macrolide (virginiamycin M1). The compounds in Group B were 
analyzed with the electrospray ionization source operated in negative ionization mode. The 
flow rate was 0.18 mL/min and 10 mM ammonium acetate (mobile phase A) and 100% 
HPLC grade acetronitrile (mobile phase B) was used for the binary gradient elution.  The 
mobile phase gradient elution was as follows: at 0 min A/B was 90:10, at 15 min A/B was 
20:80, at 18 min A/B was 90:10 and remained at this gradient until the end of the 28 min run.  
Details on the MRM ion transitions, collision energies and dwell times for analytes in Group 
B are summarized in Table 2.3. 
The operating parameters for the ionization source and mass spectrometer are 
summarized in Table 2.4 for both analytical methods and were optimized when tuning the 
instrument during method development. 
2.3.7 Data Analysis 
 The Analyst® software (version 1.4.1) was used to optimize the source and compound-
dependent parameters, control the instrument, and perform data analysis.  In addition to the 
field samples being analyzed, calibration standards, spiked nanopure water samples, blank 
samples and control samples were also analyzed.  The calibration standards and control 
standards did not go through the extraction process, but were evaporated and reconstituted 
with the internal standard solution (13C6-sulfamethazine phenyl in nanopure water) before 
injection.  In contrast to other analytical methods, the calibration standards and control 
standards were prepared by spiking the analytes into a solvent solution, instead of spiking the 
analytes into a matrix solution. 
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Table 2.3: Multiple reaction monitoring (MRM) ion transitions, dwell time, and collision 
energy for each pharmaceutical of Group B. 
 







Bezafibrate 360 274 25 -25 
Carbadox 261 122 35 -25 
Chloramphenicol 321 152 25 -25 
Clofibric acid 213 127 35 -20 
Gemfibrozil 249 121 35 -15 
Ibuprofen 205 161 40 -10 
Indomethacin 356 312 25 -15 
Lasalocid A 589 235 10 -45 
Sulfadiazine sodium 
salt 249 185 15 -25 
Warfarin, minimum 307 161 10 -25 
Virginiamycin M1 524 245 35 -25 
13C6-Sulfamethazine 
phenyl 283 122 20 -30 
D6-Gemfibrozil 255 121 15 -15 









Table 2.4: Summary of electrospray ionization (ESI) source and mass spectrometer 
parameter values for pharmaceuticals analyzed in positive ionization mode and 
negative ionization mode. 
 
ESI-MS/MS Parameter Group A Group B 
Nebulizing Gas 35 psi 35 to 45 psi 
Desolvation Gas 45 psi 30 to 45 psi 
Source Temperature 500oC 400 to 500oC 
Curtain Gas 10 to 12 psi 10 to 12 psi 
IonSpray Voltage 5000 to 5200 V 4500 V 
Collisionally Activated 
Dissociation (CAD) 5 to 8 psi 5 to 8 psi 
Declustering Potential (DP) 60 V -80 to -90 V 
Entrance Potential (EP) 10 V -10 V 
Collision Cell Exit Potential 















Calculation of Recovery Rates 
Recovery rates for all analytes were determined by comparing the signal response of 
the analyte in the spiked nanopure water samples to the average signal response of the 
analytes in the control standards.  The recovery rate of the spiked analytes in the nanopure 
water samples determined the extraction efficiency of each analyte in water samples.   
 Recovery rates were also determined for the five deuterated surrogates in the spiked 
nanopure water samples and field samples.  The recovery rates for the deuterated surrogates in 
the spiked and field water samples were determined the same way as for the analytes in the 
spiked nanopure water samples.  
Quantification 
Three quantification approaches were used to determine and compare the 
concentrations of the selected pharmaceuticals in the water samples.  Two different internal 
standard calibration approaches were used.  The original quantification method involved the 
use of one internal standard, 13C6-sulfamethazine phenyl, for determining the unknown 
concentrations of the analytes in the field samples. A known concentration of the internal 
standard was added to the field samples, calibration standards and other QA/QC samples, 
before the samples were injected into the instrument.   This internal standard was used in 
quantifying all analytes in Group A and Group B.  Since this internal standard was only added 
prior to being analyzed, this compound did not correct for extraction efficiencies, but was 
used as an indicator for instrument sensitivity during the run sequence and corrected for 
sample injection problems.   
A multi-point calibration curve was used to quantify the unknown concentrations of 
the analytes in the field samples.  For each analyte, a separate calibration curve was plotted.  
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A peak area (signal response) ratio of analyte peak area to 13C6-sulfamethazine phenyl peak 
area (peak areaanalyte/peak areainteralstd) for each calibration standard (ratio on the x-axis) and a 
concentration ratio of a known analyte concentration and known 13C6-sulfamethazine phenyl 
concentration for each calibration standard (ratio on the y-axis) were plotted.  A linear 
through zero regression was used because it was the line of best fit for the concentrations in 
the calibration standards and showed good linearity with correlation coefficients usually 
greater than 0.98.   The unknown concentrations in the field samples were determine from the 
linear through zero regression line, and appropriate dilution factors were applied to determine 
the final concentration in the sample. 
The second internal calibration approach was similar to the first quantification 
method, except deuterated surrogates (D10-carbamazepine, D6-gemfibrozil and D3-ibuprofen) 
were used instead of 13C6-sulfamethazine phenyl.  In addition, this method allowed for 
extraction efficiency to be addressed, since the deuterated surrogates were added before 
extraction.  A multi-point calibration curve was used to determine the concentrations of 
carbamazepine, gemfibrozil and ibuprofen in the field samples.  A linear through zero 
regression line was applied to the concentrations and peak areas of the surrogates in the 
calibration standards.  Details of the use of the deuterated surrogates in quantifying the 
corresponding analytes in the water samples are documented in Chapter 3.  Concentrations of 
diclofenac and 4-acetamidophenol was not quantified using this approach because these 
compounds were eventually removed from the final list of analytes to investigate (Section 
2.4).  For the remainder of the analytes, this quantification method could not be applied 
because deuterated surrogates for these analytes were not commercially available at the time 
of developing this analytical method. 
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The last quantification method used in the study was an external solvent calibration 
approach.  For this method, the calibration curve is simplified, in which the analyte 
concentration and the peak area of the analyte for each calibration standard is plotted to form 
the calibration curve. Linear through zero regression was used, and the unknown 
concentrations in the field samples were determined from the calibration curve.  Since no 
standards were added prior to extraction, extraction efficiency was not addressed. 
The three quantification methods were applied to each analyte, if applicable, over the 
sampling period to compare the final concentrations reported for each quantification method.  
The purpose was to investigate how final concentrations varied depending on the type of 
quantification method used, and if matrix effects were addressed by these methods. 
2.4 Results 
2.4.1 Final List of Target Analytes 
The original list of analytes to be investigated for this project was 38 analytes (Table 
2.1).  However, the list of analytes was redefined to a total of 27 based on low recovery rates, 
missing peaks and carry-over issues observed during sample analysis.  The analytes 
highlighted in Table 2.1 were the analytes that were not quantified and removed from the 
target analyte list.  The analytes removed from the list included the five tetracyclines 
(chlortetracycline HCl, doxycycline HCl, meclocycline sulfosalicylate salt, oxytetracycline 
HCl and tetracycline), the three fluoroquinolones (ciprofloxacin, enrofloxacin and 
norfloxacin), 4-acetamidophenol, diclofenac sodium salt and monensin sodium salt.  
For the five tetracyclines and three fluoroquinolones, the peaks in the chromatograms 
showed excessive tailing and split peaks.  In some cases, the recovery rates for these 
compounds were approaching 200% or as low of 20% in the spiked nanopure water samples.  
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These compounds were also present in the blank samples and solvent samples, which suggest 
carry-over issues.   
4-Acetamidophenol was also removed from the target list because the recovery rates 
for this compound were quite low.  For 4-acetamidophenol and its deuterated surrogate, the 
highest recovery rates observed was usually 50%. 
Diclofenac sodium salt and monensin sodium salt were not included in the final list of 
analytes because these compounds were present in the blank and solvent samples during 
analysis, and variability was observed in the recovery rates between the two spiked nanopure 
water samples and between duplicate field samples, with recovery rates approaching to 200%.   
2.4.2 Recovery Rates 
The recovery rates of the 27 analytes in the spiked nanopure water samples averaged 
between 80% to 120% for most sampling months (data no shown). The recovery rates for the 
deuterated surrogates and 13C6-sulfamethazine phenyl showed similar results.  However, the 
recovery rates of the deuterated surrogates added to the field samples showed a large 
variability in recovery rates over the sampling period, from 50% to over 200% recovery in 
some cases (Table 2.5).  In general, the recovery rates for the deuterated surrogates in the field 
samples analyzed in negative ionization mode were more variable compared to D10-
carbamazepine, which was analyzed in positive ionization mode.  This was observed with the 
high recovery rates of D6-gemfibrozil and D3-ibuprofen in the raw and treated water samples 
(Table 2.5). 
Perhaps, the most interesting results from the recovery rate data was the variability 
observed for the internal standard, 13C6-sulfamethazine-phenyl, in the field samples.  Figure 
 49
Table 2.5: Range of recovery rate percentages (%) of D10-carbamazepine, D6-gemfibrozil 
and D3-ibuprofen in the raw and treated water field samples for each sampling 
month 
 
D10-carbamazepine D6-gemfibrozil D3-ibuprofen Sampling 
Month 
Raw Treated Raw Treated Raw Treated 
April 2005 50-56 52-58 92-117 99-108 160-190 187-226 
May 2005 70-80 78-85 72-90 91-102 175-198 187-234 
June 2005 63-66 37b-88 52-58 66-83 83-95 104-139 
July 2005 70-80 77-91 60-74 79-104 96-105 129-162 
August 2005 83-88 83-98 92-109 89-99 178-198 182-221 
September 2005 50-51 52-74 101-136 123-162 193-242 170-267 
October 2005 79-81 77-85 108-121 151-158 176-211 238-382 
November 2005 74-82 79-93 114-185 151-181 153-189 150-184 
December 2005 49-64 63-72 115-146 135-140 177-211 201-256 
January 2006 61-66 61-75 93-104 116-136 97-108 120-145 
February 2006 71-73 47b-82 101-108 107-115 89-123 101-108 
March 2006 57-59 57-68 107-114 108-116 122-130 131-149 
bThe lowest recovery rate is due to volume injection problems
 50
2.2 illustrates the range of recovery rates for the internal standard over the sampling period when 
400 mL raw and treated water samples were extracted.  The variability was more pronounced 
when the samples were analyzed in negative ionization mode (Figure 2.2 (a) and (b)), with 
recovery rates ranging from 20% up to 150%. The range of recovery rates for the internal 
standard analyzed in positive ionization mode was not as variability with recovery rates between 
60% to 100% in the raw and treated water samples (Figure 2.2 (c) and (d)).  The graphs in Figure 
2.2 also illustrate the consistency of the recovery rates of the internal standard between the four 
water samples collected each month.  This consistency is well displayed in Figure 2.2 (c), where 
the recovery rates for the internal standard detected in all raw water samples were similar to each 
other during each month.  This suggests that the internal standard was impacted to a similar 
degree in all raw or treated water samples from both facilities. 
The suppression of the internal standard was clearly demonstrated when 800 mL sample 
volume was extracted.  Figure 2.3 show the recovery rates of the internal standard in the 800 mL 
extracted water samples. The recovery rates in the raw water samples were below 14% when the 
internal standard was analyzed in negative ionization mode and up to 30% when the internal 
standard was analyzed in positive ionization mode. Higher recovery rates (up to 50%) of the 
internal standard were observed in the treated water samples, with higher recovery observed 















Figure 2.2: Recovery rates (%) of 13C6-sulfamethazine phenyl in 400 mL extracted water 
samples collected from both water treatment facilities from April 2005 to March 
2006 when analyzed in negative ionization mode (a) and (b) and positive 
ionization mode (c) and (d).
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Figure 2.3: Recovery rates (%) of 13C6-sulfamethazine phenyl in 800 mL extracted water 
samples collected from both water treatment facilities from November 2005 to 
February 2006 when analyzed in negative ionization mode (a) and (b) and 
positive ionization mode (c) and (d).
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2.4.3 Quantification of Analytes 
The final concentrations for all analytes were quantified using different calibration 
approaches, either an external solvent calibration or an internal standard calibration. For 
carbamazepine, gemfibrozil and ibuprofen, final concentrations were quantified by an 
additional method, in which deuterated surrogates were used as internal standards. At the time 
of method development, few isotopically labeled standards were available.  The final 
concentrations quantified by the use of isotopically labeled standards for the three human 
pharmaceuticals were compared to the other two methods to determine the variability in final 
concentrations reported if matrix effects are not addressed and inappropriate calibration 
approaches are implemented.   
Figure 2.4 demonstrates the final mean concentrations detected for gemfibrozil and 
ibuprofen in raw water samples collected from Facility A when the three different 
quantification methods were applied.  The use of 13C6-sulfamethazine-phenyl was found to 
overestimate the concentrations of gemfibrozil and ibuprofen to the greatest extent compared 
to the external calibration method and the use of deuterated surrogates as internal standards.  
The seasonal trends observed, for the most part, appeared to remain the same between the 
three methods, and therefore seasonal variability was not highly impacted by the 
quantification method applied. 
Similar to the results observed for the recovery rates, the ionization mode played a role 
in the extent of how the different quantification methods impacted the final concentrations 
reported.  In contrast, to the variability observed in the concentrations of gemfibrozil and 












Figure 2.4: Mean concentrations (ng/L) of gemfibrozil (a) and ibuprofen (b) in raw water 
samples collected from Facility A comparing the use of 13C6-sulfamethazine-
phenyl as the internal standard for quantification, external calibration 
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carbamazepine were not as impacted by the choice of quantification method used. Figure 2.5 
shows consistency between the concentrations quantified between the three different methods, 
especially for the two internal standard quantification methods.  This suggests that 13C6-
sulfamethazine-phenyl may be a reasonable internal standard for quantifying concentrations 
of carbamazepine in the water samples collected.  In addition, all three quantification 
approaches maintain the seasonal trends observed over the sampling period. Higher 
concentrations were detected by all three methods during the summer months compared to the 
winter months. 
2.4.4 Application of Analytical Method 
 The analytical method and different quantification approaches were applied to raw and 
treated water samples collected from two full scale drinking water treatment facilities, and 
raw water samples collected from groundwater wells in a Southern Ontario watershed. It was 
found that a selected group of pharmaceuticals were consistently found over the one year 
sampling period, however, most of the concentrations detected were close to their method 
detection limit (MDL).  In addition to carbamazepine, gemfibrozil and ibuprofen, the most 
frequently detected compounds included, bezafibrate, naproxen, sulfamethoxazole, 
trimethoprim and lincomycin HCl.  The concentrations detected in the water samples for 
carbamazepine, gemfibrozil and ibuprofen were quantified using three different quantification 
approaches including the use of deuterated surrogates (isotopically labeled standards).  The 
remaining compounds were quantified using an external calibration approach due to the 













Figure 2.5: Mean concentrations (ng/L) of carbamazepine in raw water samples collected 
from Facility A (a) and Facility B (b) comparing the use of 13C6-
sulfamethazine-phenyl as the internal standard, external calibration 














































































































 The three antibiotics (lincomycin HCl, sulfamethoxazole and trimethoprim) were 
detected in the raw water samples, but were not detected in the treated water samples.  Figure 
2.6 shows the mean concentrations of the three antibiotics in raw water samples collected 
from both facilities. Trimethoprim was detected at lower concentrations compared to the other 
two antibiotics, with the highest mean concentration of 10.1 ng/L (November 2005) in the 
samples collected from Facility A and 7.9 ng/L (December 2005) in samples collected from 
Facility B.  In general, most of the concentrations detected were at or below the MDL of 10 
ng/L for trimethoprim.  Minimal seasonal trends were observed for trimethoprim with slightly 
higher concentrations detected during late spring/early summer, and then higher 
concentrations detected in the fall.  Lincomycin HCl and sulfamethoxazole were detected at 
higher concentrations compared to trimethoprim, with higher mean concentrations detected in 
the raw water samples collected from Facility B for both compounds (Figure 2.6).  The 
highest mean concentration for lincomycin HCl was 38.3 ng/L (April 2005) and the lowest 
mean concentration was 1.3 ng/L (September 2005) for samples collected at Facility A.  For 
samples collected from Facility B, the range of mean concentrations of lincomycin HCl was 
1.2 ng/L (July 2005) to 27.2 ng/L (December 2005). For sulfamethoxazole, the highest mean 
concentration was detected in November 2005 at 25.2 ng/L and the lowest mean 
concentration was 2.9 ng/L in April 2005 for samples collected from Facility A.  The 
concentrations of sulfamethoxazole for raw water samples collected from Facility B ranged 
from 5.5 ng/L (April 2005) to 34.9 ng/L (November 2005).   
 Lincomycin HCl and sulfamethoxazole showed opposite seasonal trends with 
higher concentrations detected for lincomycin HCl in the spring and late fall/winter months, 











Figure 2.6: Mean concentrations of lincomycin HCl (a), sulfamethoxazole (b) and 
trimethoprim (c) in raw water samples collected from Facility A and Facility B 


























































































































































































































































































































 Naproxen was detected at relatively high concentrations in the raw water samples 
collected at both facilities compared to other compounds investigated.  In general, higher 
concentrations were detected in water samples collected from Facility A compared to Facility 
B (Figure 2.7).  The highest mean concentration was 64.0 ng/L for naproxen (March 2006) in 
raw water samples collected from Facility B, and the highest mean concentration of 45.8 ng/L 
(September 2005) in raw water samples collected from Facility A.  The seasonal variability 
for naproxen was not well defined with higher concentrations of naproxen present in water 
samples collected from Facility A in late spring/early summer and then again in the fall 
months.  The seasonal variability of naproxen in the raw water samples collected from 
Facility B over the sampling period did not show the higher concentrations in the late 
spring/early summer months, but did show the higher concentrations in the fall months.  In 
addition, there appeared to be a peak in concentration of naproxen in the raw water samples 
collected in March 2006 at Facility B. 
Bezafibrate was one of the few compounds detected, which was found in both the raw 
water and treated water samples.  In general, bezafibrate was not detected in the treated water 
samples collected at Facility A, but was found at detectable levels in the treated water samples 
collected from Facility B.  Bezafibrate was found at higher concentrations in water samples 
collected from Facility B compared to Facility A.  The concentrations were usually below 10 
ng/L, with higher concentrations detected in the fall months (Figure 2.8).  In most sampling 
months, the percent differences showed reduction of bezafibrate, but in some cases higher 
 concentrations were detected in the treated water samples collected from Facility B. 
The highest mean concentrations of bezafibrate in the raw and treated water samples collected 











Figure 2.7: Mean concentrations of naproxen in raw water samples collected from Facility 


















































































Figure 2.8: Mean concentrations and percent differences ([Conc.raw – 
Conc.treated]/[Conc.raw] ×100) of bezafibrate in raw and treated water samples 




























































































































 Carbamazepine, sulfamethoxazole and lincomycin HCl were the only compounds 
detected in the water samples collected from the groundwater wells.  All three compounds 
were detected on each of the two sampling days at Well G, but only carbamazepine and 
lincomycin HCl were detected on both sampling days at Well H.  The concentrations detected 
at the groundwater wells were lower then the concentrations detected at the two water 
treatment facilities during the same time period, with concentrations at or below their MDLs.  
Concentrations of lincomycin HCl, sulfamethoxazole and carbamazepine detected in the 
groundwater wells are summarized in Table A13.  
2.5 Discussion 
 This study was one of the first to critically evaluate the application of liquid 
chromatography coupled with electrospray ionization tandem mass spectrometry (LC-ESI-
MS/MS) in determining the presence of pharmaceuticals in water samples, in which different 
quantification methods were applied.  The purpose was to determine the extent matrix effects 
have on quantifying selected pharmaceuticals in raw water and treated water collected from 
two water treatment facilities in Southern Ontario, Canada.   
The results from this study indicate the importance of addressing matrix effects when 
determining the presence of pharmaceuticals in environmental matrices. The use of an internal 
standard (preferably isotopically labeled surrogate) for each analyte has shown to be one of 
the best choices for addressing potential matrix effects (Richardson and Ternes, 2005; 
Hernando et al., 2006; Hummel et al., 2006; Vanderford and Snyder, 2006).  These 
isotopically labeled surrogates have very similar physical and chemical properties to the 
analyte of interest, have similar retention times and undergo the same degree of ionization in a 
source interface (Hernando et al., 2006).   The use of D6-gemfibrozil, D3-ibuprofen and D10-
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carbamazepine as isotopically labeled standards for the determination of gemfibrozil, 
ibuprofen and carbamazepine corrected for possible matrix effects as well as extraction 
efficiency.  The comparisons made between the use of isotopically labeled surrogates, the use 
of 13C6-sulfamethazine phenyl as an internal standard or the application of an external 
calibration approach showed how final concentrations can be overestimated or underestimated 
and inaccurate final concentrations reported (Figure 2.4).  The low and variable recovery rates 
of 13C6-sulfamethazine phenyl in the field samples (Figure 2.2), and the discrepancies 
between the recovery rates of 13C6-sulfamethazine phenyl and the isotopically labeled 
surrogates in the field samples suggest that 13C6-sulfamethazine phenyl was not an appropriate 
internal standard for representing how the analytes were acting in the matrix and what degree 
of ionization the analytes underwent in the interface.  Figure 2.4 illustrates the variation in 
final concentrations of gemfibrozil and ibuprofen in raw water samples collected over a one 
year sampling period when 13C6-sulfamethazine phenyl was used compared to when 
isotopically labeled surrogates were applied.  The overestimation of the final concentrations 
of ibuprofen and gemfibrozil when using 13C6-sulfamethazine phenyl as the internal standard 
is most likely the result of this internal standard being suppressed in the surface and treated 
water samples.  The suppression of the signal for 13C6-sulfamethazine phenyl resulted in the 
peak area ratio to be higher and therefore the calibration curve to be enhanced.  The 
enhancement of the curve resulted in the unknown concentrations of the analytes to be higher.   
Cahill et al. (2004) illustrated the importance of selecting an internal standard that is 
impacted to the same degree as the analyte in different matrices.  The authors showed that 
13C-caffeine was not impacted by the matrix the same way as some of the analytes being 
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investigated.  This resulted in another labeled internal standard being introduced which was 
not as impacted by the matrix and eluted from the separation column at a later time.   
The same discrepancy was not observed when comparisons were made between the 
use of D10-carbamazepine as an internal standard and 13C6-sulfamethazine phenyl as an 
internal standard.  In this case, 13C6-sulfamethazine phenyl was a good choice for quantifying 
the concentrations of carbamazepine in this study because similar final concentrations were 
reported for the two different internal standard calibration approaches (Figure 2.5).  One 
would assume that carbamazepine and 13C6-sulfamethazine phenyl interacted with the matrix 
and underwent the same degree of ionization.  This can also be explained by the higher and 
more constant recovery rates of 13C6-sulfamethazine phenyl when analyzed in positive 
ionization mode. Similar results have shown that signal suppression is greater for analytes 
analyzed in negative ionization mode compared to positive ionization mode.  
 Gómez et al. (2006) showed lower signal suppression (45%) when analytes were 
analyzed in positive ionization mode.  For analytes analyzed in negative ionization mode, 
signal suppression was greater at 60%.  Carbamazepine was one of the few compounds 
investigated by Gómez et al. (2006), in which the degree of matrix suppression was minimal.  
The results from Gómez et al. (2006) study also showed that the degree of signal 
suppression is sometimes dependent on where the analytes elute during separation in the 
chromatographic column, with some compounds eluting at the beginning or end of the 
chromatographic separation having greater signal suppression. Hernando et al. (2006) showed 
similar results, but with greater signal suppression for the analytes eluting at the beginning of 
the LC gradient. Vieno et al. (2006) reported higher signal suppression for analytes having a 
longer retention time.  For the current study, ibuprofen, gemfibrozil and carbamazepine eluted 
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from the LC column during the middle of the run, with retention times of approximately 11.4 
min, 14.3 min and 8.7 min, respectively. 
Based on the recovery rates of 13C6-sulfamethazine phenyl between positive and 
negative ionization modes, analytes analyzed in positive ionization mode were less impacted 
by matrix effects.  Similar results were observed for statin drugs, in which positive ionization 
mode was more sensitive then negative ionization mode (Miao and Metcalfe, 2003). Hilton 
and Thomas (2003) found that the internal standard, 13C-phenacetin, showed higher sensitivity 
in positive ionization, but poor ionization in negative mode.  
  An explanation for signal suppression being more apparent in negative ionization 
mode is that the formation of deprotonated analytes maybe more difficult to achieve in the 
presence of matrix components, and some mechanism could be preventing the deprotonated 
analytes from moving to the droplet surface and being effectively ionized.  Until the 
mechanism of how ionization occurs in an ESI source is determined, it will be difficult to 
conclude why the polarity is influencing ionization efficiency of certain analytes.  It would be 
beneficial to observe if other analytes analyzed in positive ionization mode are impacted to 
the same degree as carbamazepine, but this observation could be related to the persistence and 
resistant this compound exhibits in the natural environment and during treatment (Clara et al., 
2004; Ternes et al., 2004; Hummel et al., 2006).  It has been well documented that 
carbamazepine is persistent in different environmental matrices and a good marker for 
determining the presence of wastewater contamination (Clara et al., 2004).  Environmental 
fate studies investigating the movement of carbamazepine in soil and groundwater aquifers 
have shown minimal removal and similar results have been observed in wastewater treatment 
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systems (Ternes, 1998; Stamatelatou et al., 2003; Clara et al., 2004; Strenn et al., 2004; Miao 
et al., 2005; Gómez et al., 2007). 
The results from this study also support previous studies in which there is a 
relationship in recovery rates of analytes to the amount of matrix present in the sample.  In 
general, recovery rates are usually lower in samples with more matrix present (e.g. soils, 
wastewater treatment effluents) compared to samples with less matrix present (e.g. drinking 
water, groundwater) (Hirsch et al., 1998; Miao and Metcalfe, 2003; Cahill et al., 2004; 
Hernando et al., 2006; Hummel et al., 2006).  Cahill et al. (2004) investigated recovery rates 
of selected compounds in raw water samples to the recovery rates in organic-free reagent 
water.  Some compounds showed similar recovery rates between the two matrices, like 
trimethoprim and ibuprofen, while others like gemfibrozil and sulfamethoxazole were 
suppressed in the surface water compared to the reagent water samples.  Trimethoprim 
maintained a relatively constant concentration in serial dilutions of surface water with high 
dissolved organic matter compared to the other compounds tested.  The impact that the matrix 
has on a compound is dependent on the analyte of interest as well as the composition of the 
matrix. The same matrix may have different degrees of ion suppression or enhancement when 
investigating different analytes (Miao and Metcalfe, 2003).  Vanderford et al. (2003) 
investigated the presence of matrix effects using LC-ESI-MS/MS by spiking antibiotics and 
acidic drugs in surface water samples and the methanol samples. Trimethoprim was found to 
be least impacted by the surface water matrix with a percent change of 11% between the 
spiked solvent solution and the spiked surface water sample.  For naproxen, which was 
analyzed in negative ionization mode, there was 85% change between the spiked solvent 
solution and the spikes surface water samples (Vanderford et al., 2003).   
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Ion suppression of carbamazepine ranged from just over 10% in river water to up to 
60% for wastewater samples (Hummel et al., 2006). The ion suppression can be explained by 
the increase in matrix components present in the wastewater samples and therefore more 
competition with the analyte in the ionization source. This relationship was illustrated to some 
extent in this study, with lower recovery rates, as well as more variability, in the raw water 
samples compared to the treated water samples.  It was well defined when a larger volume of 
sample was extracted.  Figure 2.3 shows that increasing the volume extracted to 800 mL can 
dramatically impact the recovery of 13C6-sulfamethazine phenyl. Ion suppression, and to a 
lesser extent ion enhancement, of the deuterated surrogates in the field samples was also 
observed based on the recovery rates of these compounds in 800 mL extracted samples but to 
a lesser extent then 13C6-sulfamethazine phenyl.  In most cases, recovery rates of D3-ibuprofen 
and D6-gemfibrozil in the 800 mL extracted samples were different compared to the recovery 
rates of 13C6-sulfamethazine phenyl analyzed in negative ionization mode.  The recovery rates 
of D10-carbamazepine and 13C6-sulfamethazine phenyl in 800 mL extracted samples analyzed 
in positive ionization mode were similar to each other. 
Figure 2.4 and 2.5 also indicates to some extent that the choice of quantification 
method used does not have a dramatic impact on the seasonal trends observed. In general, 
similar seasonal trends determined by the deuterated surrogates were maintained when the 
external standard approach was applied, and to a lesser extent, when 13C6-sulfamethazine 
phenyl was used.  Seasonal trends were also found to be similar between the external 
calibration approach and 13C6-sulfamethazine phenyl quantification approach for compounds 
with no isotopically labeled standards applied in the method (data not shown). This suggests 
that although, final concentrations cannot be determined accurately using 13C6-sulfamethazine 
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phenyl or the external calibration approach, relative seasonal trends can be determined 
without the use of deuterated surrogates for the analytes investigated and the composition of 
the matrices used in this study. 
Based on the discussion about the importance of addressing matrix effects, the final 
concentrations reported in the water samples from the drinking water treatment systems in 
Southern Ontario should be taken with caution when isotopically labeled standards were not 
applied. The final concentrations for most analytes were quantified by an external calibration 
approach or by the use of 13C6-sulfamethazine phenyl. In either case, matrix effects were not 
addressed for these analytes.  Figures 2.6 to 2.8 show the final concentrations quantified by 
the use of an external calibration approach.  Despite the limitations of this analytical method 
of not addressing matrix effects, similar methods have been used in the literature (Hirsch et 
al., 1998; Castiglioni et al., 2004; Bendz et al., 2005; Castiglioni et al., 2005; Hao et al., 2006; 
Lissemore et al., 2006).  
A limited number of compounds were detected in the water samples collected from 
Facility A and Facility B. A total of five analytes (excluding carbamazepine, gemfibrozil and 
ibuprofen) were detected in the raw water samples, and only one analyte was detected in the 
treated water samples.  In most cases, the final concentrations reported were below their 
MDLs, but were still reported for qualitative purposes and to show possible seasonal 
variation.   
The presence of the three antibiotics, bezafibrate and naproxen have been detected in 
surface waters in North America (Kolpin et al., 2002; Boyd et al., 2004a; Metcalfe et al., 
2003b; Kolpin et al., 2004; Stackelberg et al., 2004; Hao et al., 2006; Hua et al., 2006b; 
Lissemore et al., 2006), and globally (Ternes, 1998; Stumpf et al., 1999; Heberer, 2002a; 
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Heberer et al., 2002; Thomas and Hilton, 2004; Bendz et al., 2005; Kim et al., 2006). The 
absence of most of these compounds in finished drinking water correlates with previous 
studies (Boyd et al., 2003; Stackelberg et al. 2004; Hua et al., 2006a; Hummel et al., 2006; 
Kim et al., 2006).   
The presence of naproxen in environmental samples has been dominant with higher 
concentrations detected in wastewater treatment effluent samples and surface waters 
compared to other pharmaceuticals (Öllers et al., 2001; Boyd et al., 2003; Boyd et al., 2004a; 
Brun et al., 2006; Hua et al., 2006b; Lishman et al., 2006; Zhang et al., 2007). The current 
study showed a similar pattern with high concentrations of naproxen detected in the raw water 
samples compared to bezafibrate and the antibiotics. In Canada, naproxen is used 
predominantly as a human anti-inflammatory agent and is a commonly prescribed non-
steroidal anti-inflammatory drug (NSAID) (Brun et al., 2006).  There are a total of 46 
products containing naproxen commercially available in the Canadian market and registered 
on Health Canada’s Drug Product Database (Health Canada, 2006). The higher concentrations 
of naproxen detected in the raw water samples collected from Facility A and Facility B during 
the fall months could be explained by the population increasing their consumption of 
naproxen during flu and cold season (Tixier et al., 2003). A similar pattern was observed for 
ibuprofen with higher concentrations detected in the water samples collected during the fall 
and winter months (i.e. flu and cold season). 
Limited work has investigated the removal of naproxen during drinking water 
treatment processes, but Boyd et al. (2003) reported naproxen to be below the detection limit 
after the addition of chlorine and filtration. The absence of naproxen in treated water samples 
is to be expected due to high reductions (greater than 80%) in concentrations during 
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conventional wastewater treatment processes (Lishman et al., 2006) and its reactivity to 
chlorine (Boyd et al., 2004b; Pinkston et al., 2004).  Boyd et al. (2004b) investigated the 
removal of naproxen in synthetic waters with the addition of free chlorine and found that free 
chlorine reacted rapidly with naproxen at pH values 5 to 9.  Similar results were observed by 
Pinkston et al. (2004), in which free chlorine attacked the aromatic ring of naproxen and 
resulted in complete transformation of this compound.  The application of powdered activated 
carbon (PAC) was also found to have an impact on the reduction of naproxen during 
stimulated drinking water treatment processes, with reductions greater than 50% for all four 
water matrices used during the study (Westerhoff et al., 2005).  Naproxen was also found to 
be oxidized by ozone with an average percentage oxidized of 91% (Westerhoff et al., 2005).  
The reduction of naproxen by PAC and ozone is consistent with similar treatment processes 
used at Facility B and Facility A, respectively.  
Studies have also shown that photodegradation may be a natural elimination process 
for the removal of naproxen in surface waters (Boreen et al., 2003).  The photodegradation of 
naproxen may help explain the overall lower concentrations of naproxen in the raw water 
samples collected from Facility B because the source raw water entering Facility B has a 
longer retention time in a small canal compared to Facility A which draws water from the 
main river system.  The higher concentrations in the fall and winter months for samples 
collected at Facility B maybe the result of ice and snow covering the water surface and 
therefore naproxen not being photodegraded to the same extent as during the spring and 
summer months.  Öllers et al. (2001) and Tixier et al. (2003) reported lower concentrations 
and higher removal of naproxen in the epilimnion (upper portion of the lake) compared to 
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hypolimnion, which could be a result of photodegradation occurring in the upper part of the 
lake water column and warmer temperatures helping the reduction of naproxen.   
The seasonal variability of naproxen in the raw water samples collected from Facility 
A may be explained by changes in water flows.  Some studies have shown that increases in 
water flow results in higher concentrations of pharmaceuticals (Tixier et al., 2003).  The 
presence of naproxen has been found at higher concentrations during high flow conditions by 
Tixier et al. (2003), however the increases in water flows during the spring and winter months 
does not completely follow the observed concentration peaks in the current study, therefore 
suggesting other processes are taking place. 
The most established seasonal trends for the compounds detected were observed for 
lincomycin HCl and sulfamethoxazole.  Higher concentrations of lincomycin HCl were 
detected in the spring and fall months compared to the summer months (Figure 2.6).  This can 
be explained by its predominant used as a veterinary antibiotic, it presence as a medicating 
agent in livestock feed and how this compound enters surface waters (Health Canada, 2006; 
Canadian Food Inspection Agency, 2004).  This antibiotic is excreted by livestock animals as 
the parent compound or as a metabolite, and then the livestock manure is applied to 
agricultural land during the spring and fall months as a soil amendment to fields.  The higher 
concentrations of lincomycin HCl in the raw water correspond to when livestock manure 
would be applied to agricultural fields and the greatest potential of surface runoff after land 
application.   
For sulfamethoxazole, a predominantly used human antibiotic, higher concentrations 
were detected in the summer and the early fall months (Figure 2.6).  The seasonal trends 
observed for this compound were opposite to the trends observed with lincomycin HCl.  One 
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possible explanation for the higher concentrations of sulfamethoxazole in the summer and 
early fall months could be due to the decrease in river flow and levels, and as a result an 
increase in the percentage of wastewater effluents that comprised the volume of the river.  
Similar seasonal trends have been observed for other pharmaceuticals, in which higher 
concentrations of the pharmaceuticals are present during low flow conditions (Metcalfe et al., 
2003b; Tixier et al., 2003; Kolpin et al., 2004; Lissemore et al., 2006; Loraine and Pettigrove, 
2006).  Kolpin et al. (2004) showed that lincomycin, sulfamethoxazole and trimethoprim were 
detected during low flow conditions, but were not detected during normal or high-flow 
conditions of streams in Iowa.   
The absence of the three antibiotics in treated water samples can be explained by their 
potential to react with chlorine and ozone. Both sulfamethoxazole and lincomycin have 
reactive sites for ozone, with aromatic rings present in sulfonamides and tertiary amines 
present in most macrolides (Huber et al., 2003).  Sulfamethoxazole showed high reactivity to 
0.1 mg/L of ozone in bank infiltrated samples resulting in 70% transformation, and reactivity 
to an ozone dose of 0.5 mg/L in surface water samples resulting in over 95% transformation 
(Huber et al., 2003).  Chlorinated drinking water samples taken from a drinking water 
treatment facility in the United States showed that trimethoprim and sulfamethoxazole had 
intermediate reactions with free chlorine residuals at 1.2 mg/L after 24 hours and complete 
reactivity with free chlorine after 10 days (Gibs et al., 2007).  Lincomycin showed complete 
reaction with free chlorine within 24 hours (Gibs et al., 2007).  The absence of these 
antibiotics in treated water samples correspond with data showing the reduction of these 
compounds during different treatment processes.  Bezafibrate was the only compound 
(excluding carbamazepine, gemfibrozil and ibuprofen) that was found in treated water 
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samples during the sampling period, and the first to be reported in North America.  To our 
knowledge, bezafibrate has only been detected in treated water samples once before with a 
concentration of 27 ng/L in German tap water samples (Jones et al., 2005). Although, the 
reported concentrations of bezafibrate in the water samples should be taken with caution 
based on the lack of an isotopically labeled surrogate for bezafibrate to address matrix effects 
and the concentrations at or below the MDL of 5 ng/L, the presence of this compound shows 
differences in the ability of the two facilities to reduce the concentrations of bezafibrate.   
There has been minimal work investigating the possible elimination processes for this 
compound, but appears to follow the same pattern observed with carbamazepine during water 
treatment processes. In contrast to carbamazepine, bezafibrate was removed or transformed 
during wastewater treatment processes (Ternes, 1998; Stumpf et al., 1999; Strenn et al., 2004; 
Castiglioni et al., 2006), but minimal work has investigated the removal of bezafibrate during 
drinking water treatment processes (Ternes et al., 2002; Huber et al., 2003).  Ternes et al. 
(2002) concluded that bezafibrate was ineffectively removed by flocculation with iron 
chloride, had a high sorption affinity to activated carbon during the adsorption isotherm tests 
and responded well to GAC filtration.  Concentrations of bezafibrate have been reduced by 
50% with the application of 1.5 mg/L of ozone in a lab-scale ozonation experiment, and 
during full-scale water treatment processes, concentrations of bezafibrate were reduced after 
GAC filtration at one facility without any oxidation processes.  In addition, bezafibrate was 
not present after bank infiltration or after slow sand filtration processes (Ternes et al., 2002).  
Huber et al. (2003) reported that bezafibrate is oxidized to a greater extent by ozone then 
advanced oxidation processes, but has a lower rate constant with ozone than other 
compounds. For the bank infiltrated water, an ozone dose of greater than 0.5 mg/L was 
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required for 80% reactivity (transformation) of bezafibrate. A dose of greater than 1 mg/L of 
ozone was required for 70% reactivity of bezafibrate in the surface water samples.  
Bezafibrate was found to be effectively oxidized in water samples with low DOC and high 
alkalinity, which increases the ozone stability and results in bezafibrate effectively being 
oxidized directly by ozone.  It was suggested that the limited reactivity with ozone is due to a 
functional group on one of the aromatic rings.  This substitute cannot be deprotonated and 
therefore at certain pH values the rate constant with ozone is low (Huber et al., 2003).   
Although, bezafibrate may be resistant to conventional treatment processes and show 
similar persistence in the natural environment and during treatment as carbamazepine, this 
compound has the potential to be removed or transformed by advanced treatment processes.  
The application of ozone and GAC filters, which were present at Facility A, were capable of 
reducing the concentrations of bezafibrate in treated water samples at Facility A. 
The results from this study also show that bezafibrate is detected at higher 
concentrations than other fibrate drugs, which contradicts other reported concentrations with 
gemfibrozil found at higher concentrations.  The presence of bezafibrate at higher 
concentrations is unexpected because of its limited use in Canada (active ingredient in only 
two drug products commercially available) (Health Canada, 2006).  The high prevalence of 
bezafibrate and gemfibrozil was questioned by Metcalfe et al. (2003b), which found similar 
results with bezafibrate and gemfibrozil found at higher concentrations in surface waters 
compared to the highly prescribed statin drugs used by the Canadian population.   
A limited number of pharmaceuticals were detected in two groundwater wells (Well G 
and Well H).  Although sulfamethoxazole and lincomycin HCl were detected at 
concentrations below their MDLs, the results suggests that these two compounds are capable 
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of moving through soils into groundwater aquifers.  The presence of sulfamethoxazole in 
Well G (urban located well) can be explained by higher loads of this human antibiotic being 
discharged into surface waters in areas with greater population density, and as a result an 
increase potential for the wells located in a population dense area to be exposed to this 
antibiotic.   Sulfamethoxazole has been detected in groundwater wells as part of monitoring 
program in an area in Germany, with eleven samples containing this compound and a 
maximum concentration of 410 ng/L (Sacher et al., 2001).  This compound was also detected 
in three groundwater samples collected in the Netherlands with concentrations below 25 ng/L 
(Stolker et al., 2004), and groundwater samples collected in the United States (Lindsey et al., 
2001).  Recently, sulfamethoxazole has been detected in wells where agricultural land was 
irrigated with treated wastewater (Ternes et al., 2007). 
The presence of lincomycin HCl at the rural located well (Well H) can be explained by 
the application of livestock manure to agricultural fields in the fall months and runoff into the 
surface waters, however the presence of this compound at the urban located well (Well G) is 
more difficult to explain.  One possible reason is the lack of degradation of this compound in 
surface water due to lower water temperatures, less penetration of sunlight for 
photodegradation in the water, or changes in water level and water flows (rainfall events), 
which all can result in higher concentrations in surface waters and a greater potential of the 
compound to infiltrate into susceptible wells (Lissemore et al., 2006). To our knowledge, this 
is the first study to report lincomycin HCl present in groundwater wells. 
Bezafibrate and naproxen were not detected in the raw water samples collected from 
the selected groundwater wells, however studies have detected the presence of naproxen in 
groundwater wells.  One study detected the presence of naproxen in groundwater wells 
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supplying drinking water to communities in Southern France, with concentrations 0.1 to 0.2 
ng/L (Rabiet et al., 2006).  The detection limits established for the GC/MS analytical method 
used in the study were lower than the detection limit used in the current study, which may 
explain the inability to detect naproxen in these groundwater wells.  Naproxen was also 
detected in one groundwater monitoring well at 20 ng/L, in which wells are used to monitor 
the effectiveness of a soil-aquifer treatment when treated effluent is used for groundwater 
recharge (Drewes et al., 2002). 
2.6 Conclusions 
 The application of LC-ESI-MS/MS is common for determining the presence of trace 
organics in the environment, and is widely used for investigating the presence of 
pharmaceuticals in different environmental matrices.  Although, the use of LC-ESI-MS/MS is 
a sensitive tool, there are limitations that need to be addressed during method development.  
The major disadvantage is that the ESI source is prone to matrix effects, which can impact the 
accuracy and reliable of determining concentrations of pharmaceuticals in complex matrices.   
Matrix effects can be addressed by a number of different approaches, with one being 
the use of an internal standard (structural analogues or isotopically labeled standards) to 
compensate for analyte suppression or enhancement in different matrices.  Internal standard 
calibration approaches were applied in this study and showed that an inappropriate selection 
of an internal standard, 13C6-sulfamethazine phenyl, can impact the final concentrations 
reported.  The use of isotopically labeled standards was found to be the best choice in 
addressing matrix effects.   
 The use of 13C6-sulfamethazine phenyl as an internal standard was found to 
overestimate the concentrations of the analytes analyzed in negative mode, but was an 
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appropriate internal standard for carbamazepine, which was analyzed in positive mode.  
Seasonal variability was retained for the analytes when using different calibration approaches, 
but the concentrations were enhanced compared to what was estimated using isotopically 
labeled standards.  The average overestimation of the estimated final concentrations using 
13C6-sulfamethazine phenyl as the internal standard was two to three times higher compared to 
the final concentrations determined when the isotopically labeled standards were used.  The 
degree of overestimation when using 13C6-sulfamethazine phenyl was found to be compound 
dependent and sometimes dependent on the season. 
 The lack of commercially available isotopically labeled standards during development 
of the analytical method restricted the ability of most of the analyte concentrations being 
corrected for matrix effects.  The final concentrations for analytes not corrected using an 
isotopically labeled standard are reported but must be considered with caution, even though 
similar methods have been used in recent reports in the scientific literature. 
 Three antibiotics (lincomycin HCl, sulfamethoxazole and trimethoprim), bezafibrate 
and naproxen were detected frequently during the sampling period.  Bezafibrate was the only 
compound detected in the treated water samples, with higher percent reduction during 
treatment at Facility A compared to Facility B.  Bezafibrate was found to follow 
carbamazepine, in which advanced treatment processes were required for reducing this 
compound to non-detectable levels. 
 The absence of most analytes in the treated water samples collected from both 
treatment facilities, suggest that current treatment technologies are capable of reducing these 
compounds to non-detectable levels or creating transformation by-products, which cannot be 
detected using the current analytical method.  The one year sampling study provided 
 85
information on the capabilities of detecting low levels of pharmaceuticals in raw and treated 
water samples, and provided insight into the ability of two full scale water treatment facilities 
to reduce the concentrations of these compounds.  The information will provide direction into 
future research initiatives assessing the impacts of these compounds in drinking water 
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 The presence and seasonal variability of selected human pharmaceuticals in two 
Southern Ontario drinking water treatment systems and eight groundwater wells was 
investigated.  Surface water (raw water) and treated water samples were collected at both 
treatment facilities each month for a period of one year, and raw water samples were collected 
from the wells on two sample dates. Water samples were extracted by solid phase extraction 
techniques and analyzed using liquid chromatography with electrospray tandem mass 
spectrometry (LC-ESI-MS/MS). Carbamazepine, gemfibrozil and ibuprofen were detected in 
raw and treated water samples usually below 100 ng/L, with higher concentrations detected in 
the raw water samples. Carbamazepine was detected at higher concentrations during the 
summer and early fall months, while ibuprofen was detected during the fall and winter 
months.  In addition, carbamazepine was detected in groundwater wells within the same 
watershed, indicating the movement of this compound from surface waters to groundwater 
supplies.  A comparison of the treatment methods employed at the two drinking water 
facilities suggests differing treatment processes (i.e. ozonation) may differentially reduce the 
concentrations of detected compounds in drinking water.  The results from this study illustrate 
that human pharmaceuticals are present in full scale drinking water treatment facilities, and 
that some current treatment technologies are capable of reducing these compounds to non-
detectable levels. 
3.2 Introduction 
It has been well documented that pharmaceuticals are considered environmental 
contaminants (Halling-Sørensen et al., 1998; Daughton and Ternes, 1999; Jones et al., 2001; 
Heberer, 2002b) detected in a number of environmental matrices, including wastewater 
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effluent samples (Ternes, 1998; Metcalfe et al., 2003a; Stamatelatou et al., 2003; Castiglioni 
et al., 2005; Castiglioni et al., 2006).  Research has found that these compounds are not 
completely removed by conventional wastewater treatment technologies, which results in a 
major pathway for these compounds entering aquatic ecosystems (Ternes, 1998; Stumpf et al., 
1999; Miao et al., 2005; Kim et al., 2006; Lishman et al., 2006; Gómez et al., 2007).  The 
presence of these compounds in treated wastewater effluents results in a continual 
replenishment of these compounds in surface waters, many of which are used downstream for 
drinking water purposes.  
Recent advancements in environmental chemistry has allowed researchers to 
determine the presence of pharmaceuticals at low concentrations in the environment, with 
only a few studies having investigated the presence of these compounds in drinking water 
supplies (Heberer et al., 1998; Zuccato et al., 2000; Stackelberg et al., 2004; Hua et al., 2006a; 
Kim et al., 2006). There is limited data available in North America about the concentrations 
of these pharmaceuticals in drinking water, how current treatment technologies are reducing 
their concentrations in treated water and the seasonal trends observed.  Currently, there is 
some monitoring data at various locations within Canada and the United States, but no 
extensive investigation has looked at the presence of these compounds in drinking water 
systems over an extended period (Boyd et al., 2003; Stackelberg et al., 2004; Hua et al., 
2006a).  
In the current study, three human pharmaceuticals (carbamazepine, gemfibrozil and 
ibuprofen) were selected based on their presence in environmental matrices, limited 
environmental fate information and a high consumption rate in the North American 
population.  In Canada, carbamazepine, ibuprofen and gemfibrozil are active ingredients in a 
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number of drug products in the Canadian market.  Carbamazepine and gemfibrozil require a 
prescription, while ibuprofen is prescribed or can be purchased without a prescription. 
The aim of this study was to apply an analytical method using solid phase extraction 
techniques and liquid chromatography tandem mass spectrometry (LC-ESI-MS/MS) to 
determine the presence of carbamazepine, gemfibrozil and ibuprofen in two full scale 
drinking water treatment facilities in a Southern Ontario watershed. Further, this study 
investigates if concentrations of these pharmaceuticals vary seasonally and are reduced 
following water treatment. 
3.3 Materials and Methods 
3.3.1 Chemicals and Standards 
Carbamazepine, gemfibrozil and ibuprofen were purchased from Sigma-Aldrich (St. 
Louis, MO, USA), along with ammonium hydroxide (ACS reagent grade), heptafluorobutyric 
acid (HFBA), and ethylenediaminetetraacetic acid (EDTA) disodium salt dehydrate (ACS 
reagent grade).  A summary of the physical and chemical properties of the three selected 
human pharmaceuticals can be found in Table 3.1, with the chemical structures in Figure 3.1. 
Ammonium acetate (above 99% purity) was purchased from Fluka Chemika (Mississauga, 
ON, Canada). Sulfamethazine-phenyl-13C6  (13C-90%) was purchased from Cambridge Isotope 
Laboratories Inc. (Andover, MA, USA). Carbamazepine-D10 (98.2 atom %D), gemfibrozil-D6 
(2,2-dimethyl-D6, 99.7 atom %D) and (+)-ibuprofen-D3 (α-methyl-D3, 99.4 atom %D) were 
purchased from CDN Isotopes (Pointe-Claire, PQ, Canada).  These deuterated compounds 
were used to monitor extraction efficiencies, and to correct for potential matrix effects 
commonly observed with the use of LC-ESI-MS/MS instrumentation.  Methanol (distilled in 
glass grade), acetronitrile (HPLC grade), water (HPLC grade) and sulphuric acid were  
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Table 3.1: Physical and chemical properties of three human pharmaceuticals evaluated 











Carbamazepine 298-46-4 236.3 C15H12N2O 
Anti-epileptic and anti-
depressant drug 
Gemfibrozil 25812-30-0 250.3 C15H22O3 Lipid regulating drug 













Figure 3.1: Chemical structures of the selected pharmaceuticals, carbamazepine, 




































purchased from Caledon Laboratories Ltd. (Georgetown, ON, Canada), and sodium hydroxide 
pellets (ACS reagent grade) was purchased from J.T. Baker Inc. (Phillipsburg, NJ, USA) for 
preparation of a 5% sodium hydroxide solution (w/v) in nanopure water. A Barnstead 
NANOpure DiamondTM water purification system (set at 18Ω) was used to provide nanopure 
water for sample preparation and extraction.   
3.3.2 Preparation of Solutions 
Stock solutions of carbamazepine, gemfibrozil, ibuprofen, and the three deuterated 
labeled compounds (D10-carbamazepine, D6-gemfibrozil and D3-ibuprofen) were prepared by 
weighing out approximately 10 mg of the powdered neat standard and dissolving the contents 
in methanol. The final stock solution concentrations were approximately 1 mg/mL, and these 
solutions were used to prepare calibration standards and spiking solutions (including the 
mixed surrogate standard solution with the three deuterated compounds).  All standard 
solutions were stored at -20 °C.  
3.3.3 Study Sites 
 Description of Drinking Water Treatment Facilities 
  A detailed description of the two water treatment facilities, Facility A and Facility B, 
the sampling locations at the facilities and the watershed can be found in Section 2.3.3.  In 
brief, both facilities obtain their source water from the main river system with Facility B 
located further downstream of Facility A.  The locations of the drinking water treatment 
facilities relative to each other and to the wastewater treatment facilities within the watershed 
are illustrated in Figure 2.1.  
 
 94
Both facilities are considered full conventional water treatment facilities with 
coagulation, flocculation, sedimentation and filtration processes present.  The addition of 
chlorine gas and anhydrous ammonia are used for disinfection at both facilities.  The major 
difference between the two facilities is the presence of ozonation, granular activated carbon 
(GAC) filters and ultra-violet (UV) irradiation at Facility A.  Details of the operational 
parameters and treatment processes at each facility can be found in Table 3.2. 
Duplicate raw and treated water samples were collected at each facility on the first 
Tuesday of each month from April 2005 to March 2006.   Details on the sample collection 
procedures can be found in Section 2.3.3. The collection of the raw and treated water samples 
did not account for retention time during treatment.  The samples collected were analyzed for 
the presence of pharmaceuticals and general water chemistry parameters. 
Description of the GUDI Well Locations 
 
In addition to water samples being collected from the two drinking water treatment 
facilities, water samples were also collected from groundwater wells.  A total of eight 
groundwater wells were sampled, including two deep groundwater reference wells (Well C 
and Well D) and six susceptible groundwater wells under the direct influence of surface water 
(referred to as GUDI) (Well A, Well B, Well E to H).  A description of each well and the 
sample collection procedure can be found in Section 2.3.3.  In brief, all eight wells are located 
in the same watershed as the two drinking water treatment facilities. Most of the susceptible 
GUDI wells were located in rural areas, except Well G. Duplicate grab raw water samples 
were collected from each well on Tuesday September 27th 2005 and Tuesday October 11th 










































































































































































































































































































































































































3.3.4 Sample Analysis – Water Chemistry Parameters 
 A number of different analytical methods were used to analyze for general water 
chemistry parameters.  A summary of the methods used can be found in Section 2.3.4.  All 
sample analysis was conducted at the Ontario Ministry of the Environment Laboratory in 
Etobicoke, Ontario.  
3.3.5 Sample Analysis – Pharmaceuticals 
 A detailed description of the preparation and extraction of the water samples for 
pharmaceutical analysis is outlined in Section 2.3.5.  In brief, the water samples collected 
were prepared along with one blank sample and two method spike samples for a total of 
eleven samples being extracted at one time. The samples were prepared and extracted within 
24 to 36 hours after being collected.  A total volume of 400 mL was extracted after the 
samples were prepared, and appropriate spiking solutions and the mixed surrogate standard 
solution were added.  
The water samples were extracted using preconditioned Waters Oasis® HLB cartridges 
(6cc, 200mg) solid phase extraction cartridges, and the analytes were eluted using 5 mL of 
methanol.  The final extract was mixed and 1 mL was transferred to a clean 2 mL clear glass 
vial. 
 The 1 mL extracts were evaporated using a gentle stream of nitrogen gas, and were 
reconstituted by adding an aqueous solution to each vial after evaporation.  The aqueous 
solution consisted of a known volume of 13C6-sulfamethazine phenyl, which corrected for 
volume injection problems into the LC-ESI-MS/MS and to calculate absolute recovery rates.  
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The vials were placed into the freezer until analysis.  The samples were usually analyzed 
within one week of being extracted. 
3.3.6 LC-ESI-MS/MS Instrumentation 
 A detailed description of how the samples were analyzed can be found in Section 
2.3.6.  In summary, all samples were analyzed using liquid chromatography with electrospray 
ionization tandem mass spectrometry (LC-ESI-MS/MS).  The analytes were separated by an 
Agilent Hewlett Packer 1100 Series liquid chromatograph system (Mississauga, ON, Canada), 
which consisted of a vacuum degasser, binary pump, column compartment and an 
autosampler.  The sample injection volume was 20 µL, except for samples collected in April 
2005 when the injection volume was 15 µL. 
The analytes were detected using an Applied Biosystems/MDS Sciex 4000 Q Trap™ 
mass spectrometer with an electrospray ionization source interface (TurboIonSpray™) and 
multiple reaction monitoring (MRM) was selected as the scan mode to quantify the 
compounds present in the water samples.   
 The three human pharmaceuticals were analyzed according to analytical method used, 
with carbamazepine analyzed in positive ESI mode, and gemfibrozil and ibuprofen analyzed 
in negative ESI mode. For both analytical methods, the same LC column was used 
(ThermHyperSil Gold RP-C18, 2.0 mm × 100 mm, particle size of 3 µm).  For positive 
ionization mode, the flow rate was 0.2 mL/min and 0.03% heptafluorobutryic acid (HFBA) 
(mobile phase A) and 100% HPLC grade acetronitrile (mobile phase B) was used for the 
binary gradient elution.  The mobile phase gradient elution was as follows: at 0 min A/B was 
85:15, at 13 min and 15 min A/B was 0:100, at 17 min A/B was 85:15 and remained at this 
gradient until the end of the 28 min run.  For negative ionization mode, the flow rate was 0.18 
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mL/min and 10 mM ammonium acetate (mobile phase A) and 100% HPLC grade acetronitrile 
(mobile phase B) was used for the binary gradient elution.  The mobile phase gradient elution 
was as follows: at 0 min A/B was 90:10, at 15 min A/B was 20:80, at 18 min A/B was 90:10 
and remained at this gradient until the end of the 28 min run.  The column was kept at room 
temperature during LC analysis. 
 Details on the MRM ion transitions, dwell time and collision energy for the three 
analytes and deuterated compounds are located in Table 3.3.  Details of the different source 
parameters required for the ESI interface and the triple quadrupole mass spectrometer are 
summarized in Table 2.4. 
3.3.7 Data Analysis 
 The Analyst® software (version 1.4.1) was used to control the instrument, create 
acquisition methods, inject/submit the samples and perform data analysis.   
Quantification 
A multi-point internal standard calibration curve was used to quantify the 
concentrations of the three human pharmaceuticals in the water samples. The calibration 
standards were prepared with different known concentrations of the three analytes and a 
known concentration of each deuterated surrogate.  The known concentrations of analytes and 
deuterated compounds were plotted against the signal of the instrument (i.e. peak area of the 
analyte and surrogate) in each calibration standard.   A linear through zero calibration curve 
was plotted for each of the three human pharmaceuticals, with a ratio of analyte peak area to 
corresponding peak area of deuterated compound (peak areaanalyte/peak areasurrogate) on the y-








































































































































































































































(concentrationanalyte/concentrationsurrogate) on the x-axis.  The unknown concentrations in the 
field samples were determined from the linear through zero regression line, with a correlation 
coefficient (r2 value) usually greater than 0.98.    
In contrast to other analytical methods, in which the calibration standards are prepared 
in an environmental matrix, calibration standards for this method were prepared in a solvent, 
evaporated and then reconstituted with an aqueous solution (13C6-sulfamethazine phenyl in 
nanopure water).  
 It has been well documented that LC-ESI-MS/MS analysis is susceptible to matrix 
effects in which components of the matrix co-elute with analytes of interest during the 
formation of gas-phase ions in the electrospray ionization source interface.  For this analytical 
method, deuterated compounds (isotopically labeled compounds) were added into the blank 
sample, spiked nanopure water samples and field samples before extraction to determine the 
extraction efficiency of the deuterated surrogates within the different matrices and correct for 
potential matrix effects.  Without the addition of the labeled surrogates for each analyte of 
interest, it is very difficult to correct for potential matrix effects in the field samples and have 
confidence in the response of the instrument knowing that the signal could be suppressed or 
enhanced by the matrix.   
 Recovery Rates 
 Recovery rates were determined for the three analytes and deuterated surrogates in the 
spiked nanopure samples, and for the deuterated surrogates in the field samples.  The recovery 
rates were determined by comparing the peak area of the analyte or deuterated surrogate to the 
average peak area of the control standards (known volume of spiking solutions).      
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The range of recovery rates calculated for the deuterated surrogates in the raw and 
treated water samples is summarized in Table 2.5. The recovery rates for the three deuterated 
compounds in the field samples were very different from the recovery rates of these 
compounds in the nanopure water samples.  The difference in recovery rates between the 
nanopure water samples, the raw water samples and the treated water samples, confirms that 
the matrix has a significant impact on the response of the analyte during LC-ESI-MS/MS 
analysis.  The recovery rates of the deuterated surrogates in the field samples also shows that 
certain compounds are impacted to a greater extent by the matrix than other compounds. In 
general, more suppression was observed with gemfibrozil and ibuprofen, which were both 
analyzed in negative ion mode.  Carbamazepine was impacted by the matrix, but to a lesser 
degree compared to the ibuprofen and gemfibrozil.  
MDLs 
The method detection limit (MDL) was based on ten 400 mL spiked nanopure water 
replicates, and the lowest value found in the linear range of the calibration curve.  The MDLs 
for carbamazepine, gemfibrozil and ibuprofen were 1 ng/L, 1 ng/L and 5 ng/L, respectively.  
The signal to noise ratio for determining the MDLs was 3:1.   
3.4 Results 
3.4.1 Drinking Water Treatment Facility Study 
 Presence of Selected Human Pharmaceuticals 
 Carbamazepine, gemfibrozil and ibuprofen were routinely detected in most duplicate 
raw and treated water samples collected at Facility A and Facility B over the sampling period.  
In general, higher concentrations were present in the raw water samples collected from 
Facility B.  
 102
Gemfibrozil, a lipid regulating agent, was present in all raw water samples collected 
from both facilities during the sample collection period (Figure 3.2).  Although there was a 
detection frequency of 100% in the raw water samples, the mean concentrations in the raw 
water samples collected at each facility were very low, usually below 5 ng/L.  The only 
exception was for the raw water samples collected in March 2006 from Facility B, when the 
mean concentration approached 6 ng/L. The range of mean concentrations in raw water 
samples collected from Facility A was from 1.1 ng/L in December 2005 to 3.6 ng/L in July 
2005.  Higher mean concentrations of gemfibrozil were present in the raw water samples 
collected from Facility B, with a range in concentrations of 1.5 ng/L in April 2005 to 5.9 ng/L 
in March 2006.  
The mean concentrations of gemfibrozil detected in the treated water samples were 
lower at both water treatment facilities.  In some months, gemfibrozil was not detected in the 
treated water samples collected at either facility. This occurred in the spring and early summer 
months, as well as December 2005.  Concentrations of gemfibrozil present in treated water 
samples collected at Facility A were below the MDL of 1 ng/L.  For the treated water samples 
collected at Facility B, the mean concentrations were above the MDL for samples collected in 
the summer and fall months, but were below the MDL during the winter months.  The highest 
mean concentration of gemfibrozil was 2.9 ng/L in the treated water samples collected from 
Facility B in October 2005.   
Ibuprofen, an analgesic and anti-inflammatory drug, was detected in raw water 
samples collected in July 2005 and from September 2005 to March 2006 (Figure 3.3).  In 












Figure 3.2: Mean concentrations and percent differences ([Conc.raw – 
Conc.treated]/[Conc.raw] ×100) of gemfibrozil in raw and treated water samples 
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Figure 3.3: Mean concentrations and percent differences ([Conc.raw – 
Conc.treated]/[Conc.raw] ×100) of ibuprofen in raw and treated water samples 





























































































































ibuprofen detected in the raw water samples was 67%.  Higher mean concentrations of 
ibuprofen were detected in the raw water samples, except for samples collected in October 
2005 and November 2005 when slightly higher concentrations were present in the treated 
water samples collected from Facility B.  During the winter months (January, February and 
March) higher mean concentrations were detected in the raw water samples collected from 
Facility B compared to Facility A.  The opposite trend was observed for the other sampling 
months, in which higher mean concentrations of ibuprofen were detected in the raw water 
samples collected from Facility A.  The range of mean concentrations detected in the raw 
water samples from Facility A was 16.4 ng/L (February 2006) to 33.0 ng/L (March 2006).  In 
the raw water samples collected at Facility B, there was more variability in the concentrations 
detected.  The lowest mean concentration detected at this facility was 9.4 ng/L (July 2005) 
and highest mean concentration was 51.6 ng/L (March 2006). 
Ibuprofen was detected in only half of the treated water samples collected during the 
sampling period at Facility A.  Detectable concentrations of ibuprofen were found in July 
2005 and November 2005 to March 2006.  The highest mean concentration was found in 
December 2005 at 15.3 ng/L, and the lowest mean concentration was found in the treated 
water samples collected in January 2006 at 7.1 ng/L at Facility A.  The mean concentrations 
of ibuprofen in the treated water samples collected from Facility B were more variable, with 
concentrations ranging from 7.5 ng/L to 41.7 ng/L.  Detectable concentrations of ibuprofen in 
treated water samples were found in more sampling months at Facility B compared to Facility 
A, in which ibuprofen was found in samples collected in September and October 2005.   
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Carbamazepine is a prescribed pharmaceutical mainly used in the treatment of 
epilepsy, but can also be used to treat some types of depression.  Carbamazepine was detected 
in all raw water samples collected at both facilities, with higher concentrations detected in the 
samples collected at Facility B (Figure 3.4).  The mean concentrations detected in the samples 
collected at Facility B were 2 to 3 times higher than the concentrations detected at Facility A 
in the raw water samples.  The only exception was August 2005, when the mean 
concentration of carbamazepine in the raw water samples collected at Facility B was close to 
1µg/L.   
The concentrations of carbamazepine detected at Facility A ranged from 2.8 ng/L in 
April 2005 to 27.6 ng/L in July 2005 in the raw water samples.  The concentrations detected 
in the raw water samples collected from Facility B covered a wider range, with the lowest 
mean concentration of 7.8 ng/L and the highest mean concentration of 988.3 ng/L (Figure 
3.4).   
In contrast to ibuprofen and gemfibrozil, carbamazepine was not detected in any of the 
treated water samples collected at Facility A during the sampling period.  However, 
carbamazepine was detected each month in all treated water samples collected from Facility 
B.  The maximum mean concentration of carbamazepine in the treated water samples was 
713.6 ng/L in August 2005. 
Percent Differences in Concentrations 
The percent differences of the three human pharmaceuticals were calculated based on 
the mean concentrations found in the raw and treated water samples during the sampling 
period.  The percent differences should be interpreted carefully because sample collection did 











Figure 3.4: Mean concentrations and percent differences ([Conc.raw – 
Conc.treated]/[Conc.raw] ×100) of carbamazepine in raw and treated water 
samples collected from Facility A (A) and Facility B (B) from April 2005 to 


























































































































difference of gemfibrozil was found to be variable over the sample collection period, 
especially at Facility B.  Higher percent differences were observed at Facility A, with percent 
differences ranging from 32% to 85% (Figure 3.2).  In general, higher percent differences  
were observed in samples collected in the summer and early fall months.  The percent 
difference of gemfibrozil at Facility B was more variable, ranging from 2% to 89%.  Higher 
percent differences were observed in the winter months at Facility B, which was the opposite 
trend observed at Facility A.  The 2% difference of gemfibrozil at Facility B in October 2005 
was an exception compared to the percent differences observed during the other sampling 
months (Figure 3.2).   
The percent difference of ibuprofen in the water samples collected at both facilities 
shows that Facility A is more effective at reducing ibuprofen to non-detectable levels.  The 
percent difference of ibuprofen during treatment was between 31% and 72% at Facility A, in 
comparison to a maximum percent difference of 40% at Facility B.  In October and November 
2005, ibuprofen was found at higher concentrations in the treated water samples collected at 
Facility B compared to the raw water samples.  
The percent difference of carbamazepine in the water samples collected from Facility 
A was the most significant with 100% difference for each sampling month.  These results 
show that the treatment processes at Facility A were able to reduce the concentrations of 
carbamazepine to non-detectable levels in the treated water samples for all sampling months.  
The treatment processes at Facility B were not as efficient in reducing carbamazepine in the 
treated water, with percent differences ranging from16% to 61%.  The lowest percent 
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difference was for samples collected in November and the highest percent difference was for 
samples collected in February. 
Seasonal Variability 
There were no distinct seasonal trends observed with the concentrations of gemfibrozil 
in the water samples collected over the sampling period.  The low concentrations detected 
made it difficult to observe any distinct seasonal trends, especially when most of the 
concentrations in the treated water samples are close to the MDL.  Distinct seasonal 
variability was observed for ibuprofen, with high concentrations (i.e. greater than 15 ng/L) 
detected in the late fall and winter months.  The most significant seasonal variability was 
observed for carbamazepine, where the highest mean concentrations were observed in the 
water samples collected in the summer and early fall months.  This seasonal trend was 
observed in water samples collected from both facilities.  In addition, the seasonal profile of 
carbamazepine also showed a large peak in the concentration of carbamazepine in August 
2005. 
3.4.2 GUDI Study 
Presence of Selected Human Pharmaceuticals 
A preliminary study investigated the presence of the three human pharmaceuticals in 
raw water samples collected from six susceptible GUDI wells and two deep groundwater 
wells in the fall of 2005.  The results showed that carbamazepine was the only target analyte 
detected in the raw water samples, with detectable concentrations found in Well G and Well 
H on both sample collection days.   
Lower concentrations of carbamazepine were detected in the GUDI wells compared to 
the concentrations detected in the raw water samples collected from the drinking water 
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treatment facility study during the fall season.  In addition, lower mean concentrations were 
present in the raw water collected from Well H compared to Well G.  Carbamazepine was  
detected at concentrations of 10 ng/L in samples collected from Well G and approximately 4 
ng/L in samples collected from Well H (Table 3.4). 
3.5 Discussion 
This study was one of the first research initiatives to investigate the presence and 
seasonal variability of carbamazepine, gemfibrozil and ibuprofen in Canadian drinking water 
supply systems.  The results from this study demonstrate that ibuprofen and carbamazepine, 
and to a lesser extent gemfibrozil, are routinely detected in water samples collected from two 
full scale drinking water treatment facilities in Southern Ontario, Canada.  The study also 
provides evidence that carbamazepine is found in groundwater supplies in Southern Ontario, 
Canada.  The concentrations detected were in the low ng/L range, which is comparable to the 
limited studies that have reported these compounds in drinking water systems (Stackelberg et 
al., 2004; Vieno et al., 2005; Hua et al., 2006a; Hummel et al., 2006; Kim et al., 2006). 
The presence of these human pharmaceuticals in the raw water samples collected from 
the two facilities was expected based on the numerous wastewater treatment facilities located 
within the watershed.  It has been well documented that treated wastewater effluents are one 
of the major pathways for pharmaceuticals entering surface waters and the aquatic 
environment (Heberer, 2002b).  Studies have shown that samples collected further 
downstream from wastewater treatment effluent discharges have lower concentrations 
detected, indicating that dilution and higher water flows have an impact on the concentrations 
of these contaminants (Stumpf et al., 1999; Metcalfe et al., 2003b; Wiegel et al., 2004; Bendz 










































































































































































































































































































































Relatively high concentrations of carbamazepine and ibuprofen were detected in the 
raw water samples collected at both facilities, despite the nearest wastewater treatment facility 
being located approximately 15 km upstream of Facility A, and relatively high water flows. 
Environmental persistence and inefficient dilution of the treated wastewater effluents provides 
an explanation of the concentrations detected in the raw water samples at both facilities. In 
addition, a large number of wastewater treatment facilities discharge into the tributaries and 
main water system of this particular watershed. The higher concentrations in the raw water 
samples could also be attributed to the inefficiency of the wastewater treatment technologies 
to reduce the concentrations of these contaminants or the effectiveness of natural 
biodegradation and sorption processes in the surface waters to lower the concentrations of 
these contaminants (Andreozzi et al., 2003; Bendz et al., 2005; Vieno et al., 2005).   
When comparing the concentrations of the pharmaceuticals found in the raw water 
samples collected from each facility, higher mean concentrations were detected in the raw 
water samples collected from Facility B.  This particular facility is located further 
downstream of Facility A, and therefore has a greater potential for source water being 
exposed to more point sources of contamination (i.e. application of biosolids to agricultural 
land).  There are a number of wastewater treatment facilities that discharge into receiving 
waters upstream of the raw water intake for Facility B.  In addition, one of the tributaries 
entering the main river system just above the intake pipe of Facility B comes from an 
intensively agricultural area, which could provide another source of contamination.  Although 
carbamazepine has been detected at higher concentrations in urbanized areas, Hao et al. 
(2006) and Lissemore et al. (2006) have detected the presence of carbamazepine in surface 
waters near agricultural inputs in this watershed.   
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For the most part, lower concentrations were present in the treated water samples 
compared to the raw water samples, which suggests that the current treatment technologies 
employed are capable of reducing the parent compound to some extent.  The only exception 
was for the water samples collected in October and November 2005 at Facility B, in which 
ibuprofen was detected at higher concentrations in the treated water samples compared to the 
raw water samples.  One possible explanation could be due to the presence of organic matter 
in the samples collected during these months and as a result extraction efficiency of the 
treated water samples being compromised.  This could also explain the low percent difference 
(about 2% difference) of gemfibrozil in the raw water and treated water samples collected in 
October 2005 from Facility B.  Another explanation for the higher concentrations of 
ibuprofen in the treated water samples could be due to the conjugated forms of ibuprofen 
entering the treatment facility being degraded during treatment and being released as the 
parent form.  Since the conjugated forms of these human pharmaceuticals were not 
investigated during this study, it is difficult to say if these ibuprofen conjugates entered the 
facility, were degraded during treatment, and then persisted in the treated water samples. 
Recent studies have suggested the cleavage of the conjugated pharmaceuticals during 
treatment processes may result in higher concentrations in the treated wastewater and water 
samples.  Ternes (1998) reported that 14% of ibuprofen is excreted in a conjugated form (i.e. 
via glucuronidation).  This would explain the increase in ibuprofen detected in the treated 
water samples by the treatment processes cleaving the glucuronide from the rest of the 
molecule.  However, one would have to assume that the wastewater treatment facilities did 
not degrade the conjugated form and this form persisted in the natural surface waters.   
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There were differences in the ability of the two facilities to reduce the concentrations 
of these compounds, with Facility A being more effective compared to Facility B. As the 
sample collection times did not take into account the retention times with the treatment 
facilities, actual removal rates could not be accurately calculated, but percent differences 
could be reported.  The percent differences compared the mean concentration in the raw water 
samples to the mean concentration in the treated water samples for each month and for each 
compound. The percent differences for gemfibrozil were higher at both facilities compared to 
the other two compounds of interest.  This would suggest that the concentrations of 
gemfibrozil were reduced to greater extent compared to ibuprofen and carbamazepine. As the 
concentrations of gemfibrozil were quite low, it was challenging to make conclusions when 
the concentrations detected were around the method detection limit for this compound.   
The percent differences for ibuprofen were quite variable, ranging from -24% to close 
to 100%.  Higher percent differences were observed for samples collected at Facility A, 
indicating that this facility is more effective in reducing ibuprofen from raw water.  However, 
relatively low percent differences were observed at both facilities compared to the removal 
rates reported for ibuprofen in previous studies, which showed greater than 80% removal 
during wastewater and water treatment (Ternes, 1998; Strenn et al., 2004; Westerhoff et al., 
2005; Kim et al., 2006). A possible explanation is the differences in treatment technologies 
available at both facilities compared to other studies.  Huber et al. (2003) and Zwiener and 
Frimmel (2000) both found that ibuprofen was not effectively removed with the addition of 
ozone, but was more effectively removed with advanced oxidation processes (i.e. ozone and 
hydrogen peroxide).   The lack of advanced oxidation processes may contribute to the lower 
removal rates of ibuprofen observed at both facilities. In addition, Castiglioni et al. (2006) 
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found that biodegradation of ibuprofen appears to be a major elimination process in natural 
waters; although other studies have suggested that log Kow value of 3.5 or higher may allow 
ibuprofen to sorb to particulate matter and be removed by sorption processes (Aston et al., 
2004).  Ternes et al. (2004) determined solid-water distribution coefficient values for a 
number of pharmaceuticals in sewage sludge, and found that sorption did not have a major 
role in the removal of ibuprofen during wastewater treatment. In either case, concentrations of 
ibuprofen can be reduced by different elimination processes and appears to be site-specific, 
and in some cases dependent on the season (Tixier et al., 2003; Castiglioni et al., 2006).   
The most interesting data reported from this study was the percent differences for 
carbamazepine between the two treatment facilities.  The percent differences between the raw 
and treated water samples was close to 100% for all samples collected from Facility A, while 
percent differences at Facility B ranged from 16% to 61%.  This suggests that the treatment 
processes used at each facility have an impact on the ability to reduce the concentrations of 
carbamazepine.  Facility A was very effective at reducing this pharmaceutical, which may be 
explained by the use of ozonation at this facility.  There is a reasonable amount of information 
in the literature that would suggest that ozone was likely responsible for the non-detectable 
levels of carbamazepine observed in the treated water samples collected from Facility A.  
Studies have shown that oxidation processes, like ozonation, are effective at reducing 
carbamazepine by greater than 90% during treatment (Ternes et al., 2002; Ternes et al., 2003; 
McDowell et al., 2005; Hua et al., 2006a). Although ozonation may not be completely 
responsible for the reduction of carbamazepine, it is a reasonable explanation for the 
differences observed between facilities.  Another possible explanation for the high removal of 
carbamazepine at Facility A is that the surface water taken from the river is stored in a large 
 119
reservoir for a selected amount of time, which may allow carbamazepine to be photodegraded.  
Limited work has investigated the degradation of carbamazepine by photolysis, but 
carbamazepine does not seem to be impacted by sunlight, especially in the presence of 
organic matter (i.e. humic acids) (Boreen et al., 2003; Vogna et al., 2004; Chiron et al., 2006).  
Chiron et al. (2006) reported that chloride may enhance photodegradation of carbamazepine 
by the chloride interacting with Fe(III) colloids under irradiation to create chloride radicals.  
A recent study by Pereira et al. (2007) investigated the reduction of carbamazepine and other 
pharmaceuticals by UV photolysis and UV/H2O2 photolysis.  The results showed direct UV 
photolysis was not effective at reducing carbamazepine, but the application of UV and 
hydrogen peroxide was effective at reducing this compound in water samples. 
The results from this part of the study show that low doses of ozone (1.5 to 3 mg/L) 
appears to be able to reduce the concentrations of carbamazepine to non-detectable levels and 
that seasonal changes in water quality and quantity do not necessarily impact the ability of 
this facility to reduce the concentrations of carbamazepine. 
The absence of ozonation in Facility B may explain the detectable levels of 
carbamazepine in the treated water samples.  Studies have demonstrated that conventional 
drinking water treatment processes are not very effective at reducing pharmaceuticals, 
especially persistent compounds, like carbamazepine (Ternes et al., 2002).  In some cases, 
advanced oxidation processes are the only treatments that are capable of reducing selected 
pharmaceuticals, in which ozone and hydrogen peroxide or UV and hydrogen peroxide are 
applied to increase the oxidants available for transforming the compounds of interest (Huber 
et al., 2003; Vogna et al., 2004; Miao et al., 2005).  In addition, recent studies have reported 
that the concentrations of some pharmaceuticals are reduced to various extents by the 
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application of new membrane technologies and innovative filtration devices (Nghiem et al., 
2005; Radjenovic et al., 2007). 
The concentrations of carbamazepine and ibuprofen detected showed seasonal 
variability.  Ibuprofen was detected at higher concentrations during the fall and winter 
months, while carbamazepine was detected at higher concentrations during the summer and 
early fall months.  The presence of ibuprofen can be explained by the increase in consumption 
of this analgesic and anti-inflammatory drug during cold and flu season (Tixier et al., 2003; 
Vieno et al., 2005).  The increase in consumption of this compound increases the amount 
being excreted and entering wastewater treatment facilities.  These facilities can be 
overwhelmed with the amount of ibuprofen entering the facility (i.e. increase in water flow 
rates), and therefore more ibuprofen is released into surface waters through treated wastewater 
effluents.  The increase in ibuprofen concentrations, and other pharmaceuticals, detected in 
surface waters may also be the result of increases in rainfall events, with treatment facilities 
having a lower efficiency during precipitation events (Tixier et al., 2003; Boyd et al., 2004a).  
Another explanation is that during the fall and winter months, the water temperature 
tends to be cooler.  The low temperatures may hinder the microorganisms in the wastewater 
treatment facilities and as a result, ibuprofen is still present after treatment.  It has been 
suggested that ibuprofen is most likely removed by biodegradation processes both in the 
natural surface waters and the treatment facilities (Andreozzi et al., 2003; Tixier et al. 2003; 
Páxeus, 2004).  The effectiveness of biodegradation is correlated to temperature, 
biodegradation decreases with decreases in water temperatures (Vieno et al., 2005).  During 
the fall and winter months, the lower temperatures would result in less biodegradation in the 
wastewater treatment facilities, which would result in the concentrations of ibuprofen not 
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being reduced as much by biodegradation processes in either the wastewater treatment 
facilities or surface waters (Andreozzi et al., 2003; Vieno et al., 2005). The process of 
photodegradation may also result in a possible elimination pathway for ibuprofen and may 
explain the higher concentrations found in the fall and winter months.  Research to date has 
shown that photodegradation is not a major elimination pathway for ibuprofen based on its 
chemical structure and resistance to absorb sunlight (Boreen et al., 2003; Tixier et al., 2003).  
Studies have shown that sorption to sediment may be a possible elimination pathway for 
ibuprofen.  An elimination rate constant for ibuprofen through sedimentation was determined 
at 0.005 to 0.01/day in a study by Tixier et al. (2003) in the epilimnion of lake water. 
Loraine and Pettigrove (2006) confirmed the presence of more compounds and higher 
concentrations detected in the dry and summer months (August to November in Southern 
California). The presence of carbamazepine in the summer and early fall months can be 
contributed to the low water levels and water flows during the hot and dry months (Hua et al., 
2006b; Loraine and Pettigrove, 2006).  Figure 3.5 illustrates the water flow levels at 
monitoring sites located upstream and downstream of the two facilities over the sampling 
period.  This figure shows that lower water flows occurred during the summer and early fall 
months, and higher flows were observed during the spring and winter months.  The lower 
water flows would result in less dilution of the treated wastewater effluents and therefore a 
higher proportion of the surface waters would be comprised of treated effluent, which could 
then be used for drinking water production.  The seasonal trends observed for carbamazepine 
cannot be explained by consumption patterns because carbamazepine is mainly used as an 












Figure 3.5: Average daily flow rates (m3/sec) at sampling sites located upstream and 
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In addition to carbamazepine being detected in the samples collected from the 
drinking water treatment facilities, this compound was also found at low concentrations in 
raw water samples collected from two groundwater well locations, Well G and Well H.  Both 
of these wells are located in the flood plain of the river, and therefore under a greater threat of 
being influenced by surface waters. Higher concentrations were present in the Well G (urban 
well) compared to the rural well (Well H). The presence of carbamazepine found at Well G 
can be explained by higher loads of this human pharmaceutical being discharged into surface 
waters in areas with greater population density, and as a result, an increased exposure for the 
wells located in a population dense area.  A study by Lissemore et al. (2006) showed similar 
results in which carbamazepine was detected at low concentrations in surface waters from 
agricultural areas and higher concentrations in surface waters collected in urbanized areas.  
The authors concluded that one reason for the presence of carbamazepine in rural or 
agricultural areas is the application of biosolids to agricultural land as a soil amendment and 
possibility of surface runoff.  The results from this study confirm the persistence of 
carbamazepine in different aquatic environments, and its ability to resist elimination processes 
(Clara et al., 2004).  Field studies have shown that this compound is not attenuated during 
bank filtration and has been detected in shallow wells, water supply wells and groundwater 
samples (Heberer, 2002b; Drewes et al., 2002; Heberer et al., 2002; Clara et al., 2004; Stolker 
et al., 2004; Rabiet et al., 2006; Ternes et al., 2007).  Gemfibrozil and ibuprofen were not 
detected in any of the selected groundwater wells investigated in the current study, but have 
been detected in groundwater wells located near contaminated surface waters in Germany at 
concentrations above 200 ng/L (Heberer, 2002a). 
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 The large peak of carbamazepine in the water samples collected from Facility B in 
August 2005 appears to be a rare event, but can be expected based on previous data collected 
by Lissemore et al. (2006) which has shown similar peaks in concentrations of 
pharmaceuticals, including carbamazepine, in the summer months. Data collected by the 
Water Survey of Canada showed that the water flow rates at a monitoring site close to Facility 
B were low, which may explain the lack of dilution of the wastewater effluents during this 
time period (Figure 3.6) (Water Survey of Canada, 2006).  However, the flow rates observed 
during the rest of the summer of 2005 were comparable.  Other possible explanations for the 
large peak in concentration of carbamazepine could be related to wastewater treatment 
facilities not operating at optimal levels, changes in surface water hydrology preventing 
elimination processes from reducing carbamazepine, the saturation of certain processes 
capable of reducing carbamazepine during this time period or the release of the parent 
compound from the conjugated form (Stamatelatou et al., 2003; Bendz et al., 2005; Lissemore 
et al., 2006). 
3.6 Conclusions 
 The study shows that carbamazepine, gemfibrozil and ibuprofen are detected in raw 
water and treated water samples collected from two full scale drinking water treatment 
facilities in a Southern Ontario watershed.  The concentrations detected were in the low ng/L 
range, which is comparable to concentrations detected throughout North America and Europe.   
In addition, this study clearly illustrates that current advanced treatment technologies (i.e. 
oxidation) applied in some drinking water systems are capable of reducing these compounds 












Figure 3.6: Daily flow rates (m3/sec) from January 2005 to December 2005 at a 



































matrices.  The consequences and possible impacts of these compounds in drinking water 
supplies are largely unknown, especially during chronic, sub-therapeutic exposure of a 
mixture of these compounds to populations who maybe immune compromised.  This study is 
one of the first to look at the presence and variability of pharmaceuticals in operational 
drinking water treatment supply systems over a long-term period (over each season).  The 
information gathered from this study will provide exposure data for selected pharmaceuticals 
in Ontario drinking water systems and serve as a starting point for attempting to assess the 
impacts of these compounds in drinking water supplies.    
  

















 This thesis investigated the occurrence and seasonal variability of selected human and 
veterinary pharmaceuticals in drinking water supply systems in a Southern Ontario watershed.  
The studies conducted provide evidence that selected pharmaceuticals, representing different 
therapeutic classes, are present in raw and treated water samples collected from two full-scale 
municipal drinking water treatment facilities, and selected groundwater wells.  The most 
frequently detected compounds were carbamazepine, gemfibrozil, ibuprofen, bezafibrate, 
naproxen, trimethoprim, sulfamethoxazole and lincomycin HCl, all of which have recently 
been identified as dominant pharmaceuticals found in the environment (Nikolaou et al., 2007). 
Three compounds, carbamazepine, lincomycin HCl and sulfamethoxazole, were also detected 
in raw water samples collected from groundwater wells within the same watershed.  To our 
knowledge, this was one of the first studies that detected bezafibrate in drinking water 
samples collected in North America, and the presence of lincomycin in groundwater supplies. 
 The presence of selected pharmaceuticals in surface water (raw water) samples was 
expected due to the large number of wastewater treatment facilities, which discharge effluent 
into the same receiving environment as the source water used for drinking water production.  
Numerous studies have concluded that wastewater treatment facilities are not effectively 
eliminating these compounds during treatment and therefore pharmaceuticals are entering the 
aquatic environment through the discharging of wastewater effluents into surface waters 
(Ternes, 1998; Stumpf et al., 1999; Ashton et al., 2004; Carballa et al., 2004; Strenn et al., 
2004; Thomas and Foster, 2005; Castigiloni et al., 2006).  Although the concentrations 
detected were below 100 ng/L for the most part, these concentrations will likely increase as 
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more wastewater treatment capacity is required to compensate for urbanization and population 
growth, and water reuse becomes more common to meet the demands of the growing 
population (Jones et al., 2005). 
This study was one of the first research initiatives to determine the occurrence of a 
wide variety of pharmaceuticals over an extended period of time in operational drinking water 
treatment facilities.  Carbamazepine and sulfamethoxazole showed similar seasonal variability 
with higher concentrations detected in the summer and early fall months compared to the rest 
of the year.  One possible explanation for this seasonal variability was the low flow conditions 
in the hot and dry summer months, and as a result less dilution of the wastewater effluent 
discharges during this time of year.  Researchers have found similar trends with higher 
concentrations of pharmaceuticals detected during low flow conditions compared to normal or 
high flow conditions (Kolpin et al., 2004; Loraine and Pettigrove et al., 2006).  Ibuprofen was 
detected most of the time during the fall and winter months, which could be explained by its 
increase use during flu and cold season, and treatment facilities not able to effectively lower 
high concentrations of ibuprofen entering the treatment facility at one time.  Another 
explanation was the wastewater treatment facilities were not operating at optimal levels 
during the winter months because the cooler water temperature decreased biodegradation 
processes, which resulted in less ibuprofen being biodegraded before being released into the 
receiving environment.   
Lincomycin HCl was detected at higher concentrations in the spring and fall months 
compared to the summer months.  One explanation for the seasonal variability was how this 
compound enters the aquatic environment. Lincomycin HCl is predominantly used as a 
veterinary drug in Canada, in which this compound would be excreted by the livestock 
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animals directly onto pasture or enter the aquatic environment by surface runoff after the land 
application of stored manure.  In Ontario, manure is applied to agricultural land as a soil 
amendment during the spring (before planting of crops) and during the fall (after harvesting 
the crops and before the ground is frozen).  The land application of manure corresponds to 
peaks in concentrations of lincomycin HCl.   
 The presence of carbamazepine, sulfamethoxazole and lincomycin in selected 
groundwater wells implies that these compounds are capable of moving through soils to 
groundwater aquifers.  The locations of the wells are in close proximately to surface waters 
and therefore the contamination was likely the result of surface waters infiltrating 
groundwater supplies.  The concentrations were lower compared to the concentrations 
detected in the raw water samples at the treatment facilities during the same time of year, 
which implies that the concentrations of these compounds are reduced to some extent by soil 
infiltration processes. 
 The ability of the two treatment facilities to reduce the concentrations of these 
compounds during drinking water production was also investigated.  In general, higher 
concentrations were detected in the treated water samples collected from Facility B compared 
to Facility A.  These differences provide evidence that water treatment technologies have an 
influence on the ability to reduce the concentrations of these contaminants during drinking 
water production.  Both facilities were able to reduce the concentrations of the three 
antibiotics and naproxen to non-detectable levels in the treated water samples, which suggests 
that the different treatment technologies applied at each facility were effective in decreasing 
the concentrations to non-detectable levels.  For carbamazepine and bezafibrate, there were 
clear differences in the capability of the two facilities to reduce the concentrations of these 
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two compounds during drinking water production.  Facility B was not very effective in 
reducing the concentrations of these compounds in drinking water, which provides evidence 
that the conventional treatment technologies used at this facility provide minimal reduction of 
these compounds from drinking water.  Facility A showed the opposite effect, in which the 
concentrations of carbamazepine and bezafibrate were reduced to non-detectable levels in 
treated water samples collected during most sampling months.  The application of ozonation 
and GAC filtration at Facility A may be responsible for carbamazepine and bezafibrate not 
being detected in treated water samples collected from this facility.  Both compounds have 
shown the ability to react with oxidants and respond effectively to GAC filtration processes.  
Another explanation for the reduction of these two compounds at Facility A was the storage 
of raw water in large reservoirs before the water entered the treatment facility.  The storage of 
the water in the reservoir may allow time for elimination processes to reduce the 
concentrations of these compounds before the water enters the facility.   
Ibuprofen and gemfibrozil were detected in treated water samples collected from both 
facilities, but higher percent differences were found at Facility A compared to Facility B.  In 
some cases, ibuprofen was detected at higher concentrations in the treated water samples 
compared to the raw water samples collected at Facility B.  This provided evidence that 
gemfibrozil and ibuprofen require advanced treatment to reduce the concentrations of these 
compounds to lower levels.  Treatment processes at either facility were not effective in 
reducing these compounds to non-detectable levels.  Previous research has suggested that 
advanced oxidation processes (e.g. ozone and hydrogen peroxide or UV and hydrogen 
peroxide) are required for the reduction of ibuprofen compared to selective oxidants, like 
ozonation (Zwiener and Frimmel, 2000; Ternes et al., 2003).  Evidence provided from this 
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project suggests that there was variability in the reduction of these compounds during water 
treatment. 
In addition to determining the occurrence, seasonal variability and potential reduction 
of these compounds during water treatment, limitations of the analytical method were also 
investigated. Although the use of LC-ESI-MS/MS instrumentation is a very sensitive and 
selective tool for determining the presence of polar organic contaminants in complex 
environmental matrices, the major disadvantage is matrix suppression or enhancement and the 
impact matrix effects have on the quantification of these contaminants in environmental 
matrices (Vanderford and Snyder, 2006; Vieno et al., 2006).  Recently studies have shown 
that the use of isotopically labeled standards is the best choice for compensating for possible 
matrix effects (Vanderford and Snyder, 2006).  These standards are able to compensate for 
matrix effects by eluting from the chromatographic column at the same time as the analytes of 
interest and undergoing the same degree of ionization in the ESI source.  Carbamazepine, 
gemfibrozil and ibuprofen were the only compounds in which isotopically labeled standards 
were available at time of method development.  Therefore, only the final concentrations of 
these three compounds were corrected for potential matrix effects (Chapter 3).  For the 
remaining compounds detected, the final concentrations could not be corrected for potential 
matrix effects, so caution must be taken when using or reporting these concentrations.  
Chapter 2 provided comparisons between the different quantification methods and the 
discrepancies in concentrations when matrix effects were not addressed.  The results showed 
that compounds analyzed in negative ionization mode were impacted to a greater degree by 
the matrix compared to compounds analyzed in positive ionization mode.  The results from 
Chapter 2 also provided evidence that the matrix effects impacted the final concentrations 
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reported, but did not have an impact on the seasonal trends observed.  Although, the 
concentrations of the three antibiotics, naproxen and bezafibrate cannot be accurately 
determined, these compounds were detected, percent differences were determined and 
seasonal variability was compared. 
 This thesis provided evidence that selected pharmaceuticals were detected in drinking 
water supplies in a susceptible Southern Ontario watershed, with a limited number present in 
treated water samples.  The compounds detected provide evidence of seasonal variability 
which can be related to consumption and use patterns, changes in water quantity and quality, 
and changes operational parameters in wastewater treatment facilities during the seasons.  The 
results also provide information on the capability of current water treatment technologies to 
reduce the concentrations of pharmaceuticals from drinking water supplies by comparing two 
facilities with different treatment processes.  For the most part, conventional treatment 
technologies (e.g. coagulation, flocculation and sedimentation) were able to reduce the 
concentrations of some compounds, however more advanced treatments were required for 
persistent pharmaceuticals. 
 The data obtained from this thesis provided information which can be used for future 
research initiatives on investigating these contaminants in drinking water supplies. It provides 
direction for which compounds should be further evaluated, what seasons are more 
susceptible to contamination, and possible treatment technologies to reduce the concentrations 
of these compounds in drinking water.  The information from this thesis provides exposure 
data in helping to support the assessment of potential implications of these contaminants in 
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